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Despite the prevalence of depression among substance users and the negative impact 
of depressive symptoms on substance abuse treatment outcomes, few interventions have 
been developed to meet the needs of depressed substance users, particularly in low-
income urban areas. The current study aimed to replicate and expand upon promising 
preliminary findings for the use of a brief behavioral activation approach [Life 
Enhancement Treatment for Substance Use (LET’S ACT; Daughters et al., 2008)] to treat 
depression in the context of residential substance abuse treatment. Extensions to the 
previous study include comparing LET’S ACT to a contact-time matched control 
treatment, Supportive Counseling (SC), and more definitively evaluating the effect of 
LET’S ACT on substance abuse treatment dropout. Results indicated that compared to 
SC, participants in LET’S ACT evidenced significantly lower rates of treatm nt dropout 
and depressive symptoms, as well as significantly higher rates of behavioral ctiv tion. 
This study builds on evidence for LET’S ACT as a short-term treatment for depression 
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Chapter 1: Introduction  
1.1 Overview 
Major depressive disorder (MDD), as well as elevated depressive symptoms, are 
highly prevalent in substance users and have significant clinical and public health 
implications, including poor substance abuse treatment outcomes and treatment dropout 
(McKay et al., 2002). Rates of substance use and depression disproportionately affect 
ethnic minorities in inner-city areas; yet unfortunately, few interventions targeting 
depression have been developed to meet the specific needs of depressed, minority 
substance users living in the inner-city (Hasin et al., 2005; Moneyham et al., 2000). One 
approach that has been suggested to be useful in this context is behavioral activation 
(BA), which treats depression by increasing individuals’ engagement in pleasant events 
to increase levels of positive reinforcement (Jacobsen et al., 1996; Lejuez et al., 2001). 
Daughters and colleagues (2008) have adapted BA to meet the specific needs of low-
income, inner-city substance users with depression, and in a preliminary pilot study for 
this treatment [Life Enhancement Treatment for Substance Use (LET’S ACT)], LET’S 
ACT was associated with a significant reduction in self-reported depressive symptoms 
and a significant increase in enjoyment and reward value of activities. Although 
preliminary findings for LET’S ACT are promising, several extensions t  this previous 
study are necessary to establish further the efficacy of LET’S ACT, including utilization 
of a contact time-matched control treatment and a larger sample size to allow for a more 
definitive evaluation of treatment dropout. Towards this end, the current study compared 
LET’S ACT to Supportive Counseling (SC) among a sample of 58 low-income substance 





Beck Depression Inventory score ≥ 12) currently receiving residential substance abuse 
treatment in N.E. Washington, D.C. to investigate the utility of LET’S ACT in reducing 
residential substance abuse treatment dropout, as well as decreasing depressiv  symptoms 
and increasing rates of behavioral activation.  
1.2 Depression and Substance Use Comorbidity  
 Major depressive disorder (MDD) and substance use disorder (SUD) are highly 
comorbid, which has significant clinical and public health implications. A national drug 
use survey revealed that 22% of individuals with an SUD also met for past year MDD 
(SAMHSA, 2004), and other studies have indicated that over 50% of illicit drug users 
present to substance abuse treatment with clinically significant depressive 
symptomatology and are in need of depression treatment (Johnson, Neal, Brems, & 
Fisher, 2006). The prevalence of SUD-MDD comorbidity is particularly relevant to 
Washington D.C., where the rate of illicit drug use is approximately 40% higher than the 
national rate (SAMHSA, 2005). Specifically, of individuals living in D.C. over 12 years 
of age, 51.2% report using illicit drugs in their lifetime, and 19.5% in the past year 
(SAMHSA, 2005). Of those presenting to substance abuse treatment centers in the D.C. 
area, MDD is highly prevalent. For example, at a 136-bed residential substance abuse 
treatment center in Northeast D.C., rates are 31% for current MDD and 41% for lifetime 
MDD at intake (n = 295; data from clinical interviews conducted at the Salvation Army 
Harbor Light Residential Substance abuse treatment Program in 2007-2008). Further, in 
inner-city areas, rates of substance use and depression disproportionately affect ethnic 
minorities, as well as those living in poverty (Hasin et al., 2005; Moneyham et al., 2000). 





been shown to be more strongly related to each other than in Caucasian samples (Jones-
Webb, Jacobs, Flack, & Liu, 1996). Thus, particularly in this population, the prevalence 
of this comorbidity represents a significant clinical and public health consideration 
(Thase, Salloum, & Cornelius, 2001).  
1.3 Depression, Treatment Dropout, and Substance Abuse Treatment Outcomes 
 The presence of MDD or elevated depressive symptoms among substance users 
has been shown to be associated with an increased likelihood of dropping out of 
substance abuse treatment (McKay et al., 2002; Tate et al., 2004; Thase, et al., 2001); 
treatment dropout is of particular importance, because treatment length is a con istent 
predictor of long-term treatment outcomes (Hubbard, Craddock, & Anderson, 2003; 
Simpson, Joe, & Brown, 1997). In a sample of illicit drug users, Brown and colleagues 
(1998) found that treatment dropout was not related to substance use severity, but rather 
was significantly correlated with baseline depression; further, higher lev ls of depressive 
symptoms during treatment were significantly associated with greater drug cravings and 
relapse (Brown, Monti, Myers et al., 1998). Numerous studies have found depression to 
be consistently associated with relapse (Hasin et al., 2002; Rounsaville, et al., 1986), 
shorter abstinence attempts following treatment (Greenfield et al., 1998), and increased 
subsequent treatment readmission rates (Alterman, McLellan, & Shifman, 1993; Moos,
Mertens, & Brenna, 1994). As a more specific example, Hasin and colleagues (2002) 
examined the timing of depressive episodes in relation to substance use remission and 
relapse in a sample of 250 substance dependent inclients. Participants were given a 
baseline assessment, and then 6-, 12-, and 18-month follow-up assessments pertaining to 





MDD at baseline were less likely to maintain remission than clients without current 
MDD. Lifetime MDD was also associated with a reduced likelihood of remission of 
substance dependence; additionally, current MDD during abstinence predicted relapse 
following discharge (Hasin et al., 2002). Given the relationship between MDD, treatment 
dropout, and substance use relapse, treating depression may be an important mechanis 
to also improve substance use outcomes.  
1.4 Existing Treatment Approaches for Comorbid Depression among Substance Users 
Despite the prevalence of co-occurring MDD and SUD and the associated poor 
outcomes, few controlled clinical trials have been performed to develop or evaluat  
psychosocial treatments for depressed substance users, particularly among low-income 
minority drug users. Further, a large majority of the work in treating this comorbidity 
involves provision of psychotropic medication, which is often difficult in inner-city 
residential substance abuse treatment centers without regular physician ac ess 
(Friedmann, Alexander, & D’Aunno, 1999). Additionally, given mixed pharmacological 
findings in treating this comorbidity (see Nunes & Levin, 2004 for a review), there 
appears to be an important role for psychosocial treatment. In particular, studies have 
indicated that the use of pharmacotherapy may lead to reductions in depression but has 
either no effect on drug use outcomes (Carroll, Nich, & Rounsaville, 1995; Cornelius et 
al., 1998; Nunes et al., 1995) or may lead to actual increases in substance use relapse 
rates compared to placebo (Schmitz et al., 2001). Carpenter et al. (2004) indicated that 
sertraline was associated only with significant decreases in depression and substance use 
when examining a positive or negative environmental context as a moderator of this 





treatment with a “behavioral intervention targeting the accessibility of reinforcement” 
given the significant moderating role of environmental context on depression and 
substance use outcomes (Carpenter et al., 2004). Taken together, psychosocial treatments 
that target depression among substance users, specifically focusing on changes in 
environmental context, may be necessary. 
1.4.1 Psychosocial Treatments for Depression among Substance Users 
The most common psychosocial intervention that has been evaluated as a 
treatment for depressed substance users is CBT (Carroll & Onken, 2005), which when 
administered as a treatment for substance use among depressed substance users is 
typically based on relapse prevention strategies (Marlatt & Gordon, 1985) and has been 
adapted specifically for cocaine users (Carroll et al., 1995). CBT for depression (CBT-D) 
is typically administered as an individual treatment and often includes daily thought and 
mood monitoring, cognitive restructuring, and social skills and assertiveness training. 
CBT-D has been shown to have a positive effect on alcohol and depression outcomes in 
alcoholics with elevated depressive symptoms (Brown, Evans, Miller, Burgess, & 
Mueller, 1997; Turner & Wehl, 1984), and similar findings have been found using CBT-
D for injection drug users meeting criteria for MDD or dysthymia (Stein et al., 2004); 
further, in this study, depression remission was associated with a reduced frequency of 
cocaine and heroin use (Stein et al., 2004). As another example of an application of CBT 
to a depressed substance using population, Brown and colleagues (2006) evaluated an 
integrated cognitive behavioral treatment (ICBT) in sample of substance dependent 
individuals with MDD. ICBT participants demonstrated significantly lower depressive 





substance use outcomes in the ICBT condition, but results did not reach statistical 
significance (Brown, Glasner-Edwards, Tate, McQuaid, Chalekian, & Granholm, 2006). 
Although the findings are not well-established, the evidence reviewed suggests that 
depression may be a potential target for future treatment outcome research aimed at 
improving substance use outcomes in these populations. 
1.4.3 Methodological Limitations of Past Research 
 Despite the clinical necessity to develop effective psychosocial treatments for 
depressed substance users, systematic, randomized controlled trials with sufficient 
sample sizes to evaluate such treatments are scarce and are met with significant 
methodological limitations. Whereas the above mentioned studies have begun to evaluate 
the efficacy of psychosocial treatments for depression in substance users (mainly CBT), 
sample sizes remain small (Brown et al., 1997), a full range of necessary outcome 
assessments are not available (e.g., substance use outcomes, Watkins et al., 2006;follow-
up depression outcomes, Brown et al., 1997), or the effects on substance use outcomes 
are not quite significant (e.g., Brown et al., 2006). Further, a large majority of studie  
evaluating psychosocial treatments for this comorbidity have been intended as tr atments 
for substance use only (see Carroll & Onken, 2007; Crits-Christoph et al., 1999 for 
reviews), thus do not include depression in the inclusion criteria and/or have only 
examined treatment’s effect on depression in secondary analyses (e.g., Carroll et l., 
1995, see Rounsaville, 2004 for a review).  
1.4.4 Application of CBT-D to Low-Income, Inner-City, Minority Drug Users: Cultural 





 Another significant consideration is the applicability of previously evaluated 
CBT-D interventions to low-income, inner-city, minority illicit drug users. Most studies 
have focused solely on treating alcoholics (e.g., Brown et al., 1997) and utilized 
predominantly Caucasian samples (e.g., Brown et al., 1997; Stein et al., 2004). Such 
findings may not be appropriately transferable to inner-city, minority illicit drug users, a 
population representing a significant portion of substance abuse treatment admissions. 
For example, in 2005, African Americans comprised 22% of national substance abuse 
treatment admissions and 51% of admissions for crack/cocaine (SAMSHA, 2006). 
Further, inner-city, minority illicit drug users often have the highest ratesof substance 
use and depression comorbidity (Huang et al., 2006; Kessler et al., 2003). Particularly 
with regard to substance abuse treatment dropout, past research has pointed to the need to 
examine specific needs of racial minorities in treatment, given that significantly fewer 
African Americans (30.7%) than Whites (46.1%) complete residential substance abus  
treatment (Jacobson, Robinson, & Bluthenthal, 2007). Challenging the appropriateness of 
current treatment approaches that can be integrated effectively into a residential 
substance abuse treatment center and applied to this underserved and understudied 
population is necessary.  
 Certain characteristics of CBT-D may hinder its ability to be incorporated in o a 
large, inner-city residential substance abuse treatment setting, particularly given limited 
resources and high client volume (Morgenstern et al., 2001). First, CBT-D has been 
shown to be too time intensive to be incorporated easily into a substance abuse treatmen  
plan due to the necessary length of sessions and treatment duration; further, CBT-D is 





administer in a substance abuse treatment setting with limited resources available for 
individual clients (Morgenstern et al., 2001). Second, the majority of therapists in 
traditional substance abuse treatment centers are not trained to implement CBT-D or 
other more complex treatments (McCoy, Messiah, & Zhao, 2002). Third, CBT-D also 
poses difficulty with regard to client comprehension. More elaborate cognitive techniques 
involving high levels of awareness of cognitions, such as cognitive restructuring, may be 
challenging in some regards for chronic drug users, who often present with limited formal 
education and/or with cognitive impairments due to the effects of long-term, ch onic 
illicit drug use. Even low levels of cognitive impairment have been shown to affect 
retention negatively in a CBT treatment for illicit drug users, perhaps due to lack of 
comprehension or inappropriateness of complex cognitive techniques (Aharonovich et 
al., 2006; see also Carroll, Kiluk, Nich, Babuscio, Brewer, Potenza, Ball, Martino, 
Rounsaville, & Lejuez, in press).  
 Feasibility of integration into a residential center is a clinical necessity due to the 
prevalence of residential substance abuse treatment provided in the U.S., particularly in 
low-income, inner-city environments, as well as due to the scarcity of mental h alth 
services available in these settings. Nationally, approximately 40% of individuals seeking 
substance abuse treatment receive residential care (according to the 2004 SAMHSA 
Treatment Episode Data Set), and in D.C. specifically, 33% of all drug/alcohol treatment 
facilities offer residential care (SAMHSA, 2006). Further, an estimate of up to 61% of 
individuals in residential substance abuse treatment centers meet for comorbid lifetime 





sufficient mental health services internally (Etheridge, Craddock, Duntema, & Hubbard, 
1995).  
1.5 Development of Depression and Substance Dependence: Reinforcement Theory 
 Considering the aforementioned limitations of CBT-D, a more straightforward 
approach based on reinforcement theory may serve as a context to understand the 
development of depression and substance use among this underserved, at-risk group. 
Although CBT-D is grounded in aspects of reinforcement theory, modifying CBT-D to 
limit its focus solely on behavioral changes may be a more appropriate, strightforward 
approach for this population.  
 According to behavioral theory, depression results from a loss of positive 
reinforcement for healthy behaviors (Ferster, 1973; Lewinsohn, 1974; Skinner, 1953). 
Loss of reinforcement may occur in the form of quantitative (i.e., number or intensity) or 
qualitative (e.g., type: social, intellectual; function: stimulation seeking, achievement) 
aspects of an event, availability of reinforcement in the environment (e.g., social 
isolation, poverty), instrumental behavior (e.g., social skill, academic ability), and/or the 
result of an increased frequency of punishment (Lewinsohn, 1974). This theory is 
supported with early work by Lewinsohn using the Pleasant Events Schedule (PES; 
MacPhillamy & Lewinsohn, 1971). Following the generation of individualized pleasant 
event schedules and subsequent monitoring of the frequency of events and daily mood 
state, depressed, non-depressed, psychiatric, and normal controls all exhibit a significant 
positive relationship between mood level and frequency of pleasant activities (Lewinsohn 
& Graf, 1973; Lewinsohn & Libet, 1972). Further, evidence indicates that depressed 





activities (Lewinsohn & Graf, 1973; MacPhillamy & Lewinsohn, 1971). Moreover, 
depressed individuals engage in fewer interpersonal behaviors, thereby suggesting th y 
may be receiving less social reinforcement (Hopko et al., 2005; Lewinsohn & Shaffer, 
1971). Finally, behavioral activation (BA) treatments that increase access to pleasant 
events and positive reinforcers, as well as decrease the intensity and frequency of 
aversive events and consequences, have been markedly successful in treating depression 
(Hopko et al., 2003; Jacobson et al., 1996; Lejuez, Hopko, & Hopko, 2001; Lejuez et al., 
2001; Martell, Addis, & Jacobson, 2001). Further, this behavioral approach has been 
shown to be as effective as cognitive behavioral therapy (CBT) in treating depression 
(Jacobsen et al., 1996; Zeiss, Lewinsohn, & Muñoz, 1979), but may not present many of 
the aforementioned limitations of CBT when applied to a low-income, inner-city, illicit 
drug using population receiving residential substance abuse treatment.  
1.5.1 Use of Behavioral Activation Treatment to Target an Increase in Reinforcement 
A brief, uncomplicated behavioral approach offers an important benefit to meet 
the unique needs of inner-city minority substance users as an alternative to CBT-D. 
Specifically, BA treatments for depression are based on reinforcement theory and are 
aimed at increasing contact with pleasant events and positive reinforcers, as well  
decreasing the intensity and frequency of aversive events and consequences (Lewinsohn 
& Graf, 1973; Lewinsohn, Sullivan, & Grosscup, 1980). This presents a functional 
approach to treating depression, focusing on activities, goal-setting, and establishing life 
values, and the fundamental themes of reinforcement overlap with typical components of 
substance abuse treatments (e.g., decreasing avoidant tendencies, improving social 





priorities). Thus, utilization of a functional reinforcement approach would target 
depressive symptoms and also potentially show substance use gains by focusing on 
practical elements such as substance-free daily activities and goals. 
As discussed previously, the main limitations of CBT-D in its application to a 
substance abuse treatment center (e.g., time intensiveness and complexity, which may 
hinder substance abuse treatment staff adoption and client comprehension) may notbe 
obstacles when using BA in this population. BA may be more easily adopted in this 
setting due to the lack of mental health specific training needed for staff, its group format, 
time efficiency (e.g., fewer and shorter sessions), and ease of comprehension by clients 
due to its uncomplicated, straightforward protocol (Daughters et al., 2008; Lejuez, 
Hopko, & Hopko, 2001). Further, a BA approach would offer significant advantages for 
individuals with comorbid depression in particular, including the ability to target nd 
address problems that arise from the unique combination of depressive symptoms and 
substance use (Rounsaville, 2004), such as increased tendency towards treatment attrition 
and relapse fueled by the comorbidity (McKay et al., 2002; Rounsaville, 2004). Changing 
one’s environment, a main target in BA, is also crucial for substance use outcomes, and 
thus may represent a key improvement from previous treatments that showed mixed 
substance use outcomes even when improving depression.  
1.6 Preliminary Support for the Life Enhancement Treatment for Depression (LET’S 
ACT) 
 Daughters and colleagues (2008) recently developed the Life Enhancement 
Treatment for Depression (LET’S ACT), which is based on the empirically validated 





2001) and has been modified to accommodate the needs and lifestyles of a substance 
using population currently receiving residential substance abuse treatment. Th  
vocabulary within the LET’S ACT manual has been simplified, and complex concepts 
and forms have been eliminated, replaced, or modified. To address both the early and late
stages of substance abuse treatment, earlier sessions focus on modifying behavior in 
treatment, while the last sessions move toward post-residential treatment discharge 
planning and goals. A more detailed description of the LET’S ACT treatment is presented 
in the Methods section. 
 In this original publication, Daughters et al. (2008) compared LET’S ACT to 
treatment as usual (TAU) in treating depressive symptoms among inner-city illicit drug 
users in an inclient treatment setting. Specifically, 44 adult illicit drug users with mild to 
moderate depressive symptoms (BDI-II ≥ 10) who were currently receiving inclient 
substance abuse treatment (contracted to ≥ 60 days of treatment) were randomly assigned 
to either treatment as usual alone (TAU) or TAU plus LET’S ACT (which was delivered 
in 6 sessions plus two review maintenance sessions following treatment). Clients were 
assessed at baseline for DSM-IV psychiatric diagnoses, depressive symptoms (HAMD, 
BDI-II), and enjoyment and reward value of activities (EROS). Clients were again 
assessed at post-treatment and a 2-week follow-up. Treatment satisfaction and dropout 
rates also were assessed at post treatment. There was a significant group x time 
interaction such that clients receiving LET’S ACT evidenced significantly greater 
improvements than the TAU only group in severity of depression [HAMD; F(1, 37) = 
7.5, p < .01, 2 = .17], enjoyment and reward value of activities at post-treatment 





[BDI-II; F(1, 30) = 6.3, p < .05, 2 = .17]. The LET’S ACT group also reported 
significantly higher treatment satisfaction ratings [F(1, 38) = 10.8, p < .01,2 = .23]. 
Treatment dropout was approximately 4.5% for LET’S ACT (n = 1) and 22.7% for TAU 
(n = 5). This difference was not statistically significant [χ2(1) = 3.3, p = .068], but the 
high odds ratio is noteworthy (B = 1.82; SE = 1.14; OR = 6.18). Taken together, this 
study provides initial support for the efficacy of LET’S ACT in treating depressiv  
symptoms and improving the enjoyment and reward value of activities among illicit drug 
users receiving residential substance abuse treatment.  
1.6.1 Extensions to Preliminary Study of LET’S ACT 
 The preliminary findings of LET’S ACT in Daughters et al. (2008) are 
encouraging, yet the study has some limitations and clear opportunities for extension, 
including the following: 1) comparison with a contact-time matched control; 2) further 
investigation of the effect of LET’S ACT on treatment dropout; 3) modification of LET’S 
ACT into a 5-session protocol to allow for inclusion of 30-day clients in order to increase 
the effectiveness of the treatment and adoptability at a residential treatment center; and 4) 
enhancing the assessment of behavioral activation to include the BADS (Kanter et al., 
2007), which was designed specifically to assess increases in behavioral actvation over 
the course of a BA-focused depression treatment.  
 First, inclusion of a contact-time matched control is necessary to enable furth r 
investigation as to whether beneficial effects of LET’S ACT are a result of the 
ingredients of the treatment and not solely the increased individualized attention. While 
treatment as usual (TAU) in Daughters et al. (2008) is a logical starting poit for a 





depression-specific, and do not cater to individuals’ specific needs. Thus, solely based on 
the findings of Daughters et al. (2008), it is difficult to discern whether the positive 
findings are a result of increased contact time and individual attention or the unique
effects of LET’S ACT, thus making the inclusion of a more active, individual control 
treatment such as supportive counseling (SC) necessary.  
 Beyond adding a contact-time matched control treatment, a second logical second
step for the current study is further investigate the utility of LET’S ACT in reducing 
treatment dropout, which was suggested in the preliminary study, but findings did not 
reach statistical significance. Treatment dropout is a significant main outcome in which 
to focus in this current study given its implications regarding long-term substance use 
outcomes; treatment length has consistently been shown to be directly related to ras of
relapse, as well as HIV risk and other negative psychosocial outcomes such as 
unemployment, homelessness, and poverty (Hubbard, Craddock, & Anderson, 2003; 
Simpson, Joe, & Brown, 1997).  
 A third future direction for the evaluation of LET’S ACT relates to its 
effectiveness and the ease of adoption in a residential facility. In the Daughters et al. 
(2008) study, participants had to hold a contract length over 60 days to be included in the 
study to have enough time at the Center to receive all 8 sessions (6 treatment sessions and 
two review maintenance sessions) following initial screening and recruitment procedures. 
Recent changes in funding for substance abuse treatment has shifted from longer to 
shorter contract lengths, with a 30 day contract now being a common length found at 
urban residential substance abuse treatment centers (for example through federal fun ing 





Addiction Prevention Recovery Administration (APRA). In turn, the 6-session (plus two 
maintenance sessions) protocol precludes enrollment of any clients with a 30-day 
contract, which comprises a large portion of clients (e.g., approximately 75% per month 
according to data collected at the Salvation Army Harbor Light from July 2008 through 
July 2009). Given the pressure to provide brief-time efficient treatments in this context, 
another future direction is to evaluate a shorter version of LET’S ACT that would 
accommodate 30-day clients. A 5-session version (which does not eliminate any material 
but rather combines session content of sessions 4-6 into two sessions) was a logical 
extension for the current study, as it would allow for 30-day clients to receive tratment 
that would begin treatment in their 2nd week at the Center and still cover all material 
covered in the LET’S ACT intervention evaluated in Daughters et al. (2008). 
 Finally, a fourth logical future direction would be to expand on the assessment of 
behavioral activation-related outcomes. Daughters et al. (2008) utilized primarily the 
Environmental Reward Observation Scale (EROS; Armemento & Hopko, 2007) to assess 
level of environmental reinforcement and reward derived from activities (known as 
response-contingent positive reinforcement) as the main behavioral activation-related 
outcome. In addition to the EROS, a measure assessing overall activity level, avoidance, 
and impairment in main life areas (work, school, social) is another dimension of 
behavioral activation commonly included in randomized controlled trials evaluating 
behavioral activation treatments (Kanter et al., 2007; 2008). The Behavioral Activation 
for Depression Scale (BADS; Kanter et al., 2007) is a 25-item self-report scale that 
assesses overall activity level, as well as specific behaviors that are hypothesized to be 





should lead to increased contact with response-contingent positive reinforcement. The 
BADS does not assess response-contingent reinforcement directly, rather whether 
individuals are making behavioral changes that should potentially lead to increased 
response-contingent reinforcement, and thus would be an important addition to the 
assessment of behavioral activation in the evaluation of LET’S ACT.  
1.7 Current Study 
The current study is a systematic replication and extension of the initial LET’S 
ACT study (Daughters et al., 2008). Extensions of the previous study include 1) 
utilization of a contact-time matched control treatment; 2) further investigation of the 
effect of LET’S ACT on substance abuse treatment dropout; 3) modification of the 
treatment manuals to deliver treatment optimally in 5 sessions to allow for inclusion of 
30-day clients to increase the utility of the treatment in today’s residential treatment 
centers; and 4) expand on the assessment of behavioral activation outcomes to include a 
measure of overall activation and behavioral changes that may lead to increased 
response-contingent reinforcement using the BADS. In sum, the current study compared 
LET’S ACT to Supportive Counseling (SC) with both groups receiving residential 
substance abuse treatment (TAU) among a sample of 58 low-income substance users with 
depression currently receiving residential substance abuse treatment in inner-city 
Washington, D.C. In a systematic replication and extension of the Daughters et al. (2008) 
study, the current study aimed to expand on this important preliminary investigation to 
investigate the utility of LET’S ACT in reducing residential substance abuse treatment 
dropout using a 5-session treatment protocol which modified the previous LET’S ACT 





participants who received LET’S ACT would evidence 1) greater reductions in substance 
abuse treatment dropout [categorical dropout (yes/no) and days to treatment dropout]; 2) 
greater reductions in depression (self-reported and clinician-rated depressive symptoms); 
and 3) greater increases in behavioral activation (measured by the EROS and BADS self-
report measures).  
1.8 Design considerations 
 Several decisions were made regarding the experimental design and 
inclusion/exclusion criteria. First, we considered what type of control or treatment 
condition we should use to compare to LET’S ACT. Several factors indicate that the 
supportive counseling comparison may be most appropriate for this particular project. 
First, the use of SC builds on the findings of Daughters and colleagues (2008) by adding 
a contact-matched control rather than using treatment as usual (TAU) as the control 
condition. Second, the proposed trial is highly preliminary and seeks to determine if 
LET’S ACT may be better than non-specific therapy factors – such as therpeutic 
alliance and contact time – each of which have been shown to be effective in reducing 
dropout in and of themselves (Horvath & Symonds, 1991; Craig, 1985). The current 
study aims to provide the groundwork prior to the consideration of a randomized 
controlled trial (RCT) with LET’S ACT and more compelling comparison conditions. SC 
is a logical first step, particularly given the resources and time limitations of the current 
project.  
A second relevant consideration was the inclusion of individuals with other 
comorbid psychopathology and/or use of psychotropic medications. Due to the high rate 





Brink, Harteveld, & van der Wielen, 1993; Ziedonis et al., 1994), it was clear that 
including such individuals would maximize external validity (Rounsaville, Weiss, & 
Carroll, 1999), and in contrast, excluding these individuals would greatly limit our 
sample. Thus, we elected to include comorbid conditions (with the exception of acute 
psychosis), and individuals taking psychotropic medications if stabilized for over 3 
months. Any group differences in comorbid diagnoses were considered as covariates in 
all analyses.  
 Third, we considered whether we should examine treatment dropout or post-
treatment relapse (using follow-up assessments) as the main substance use outcom . The 
end decision was to focus on treatment dropout for three reasons. First, individuals who 
dropout of treatment are clearly at increased risk for substance use relapseand ar  less 
likely to have received sufficient treatment to address depressive symptoms. Thus, 
treatment dropout has unique implications for dual diagnosis populations, given that the 
depression-related outcomes associated with treatment dropout may also impact 
substance use relapse. Second, the current proposal stems directly from prior work 
suggesting the utility of LET’S ACT in reducing treatment dropout; these findings were 
not quite significant but worthy of further exploration. Third, treatment dropout is the 
most feasible dependent variable of substance use outcomes given the scope and tim
limitations of the current project, and studies have indicated dropout to be a strong proxy 
for relapse (e.g., Bottlender & Soyka, 2005).  
Fourth, we also discussed the most appropriate period of time for initial 
assessment. To ensure that initial withdrawal symptoms did not interfere with an 





effects of time in treatment, participants were assessed no sooner than 48 hours and no 
later than 7 days after they arrive at the facility. It should be noted that individuals must 
have passed through detoxification and be completely free of drugs at intake, thereby 
limiting the likelihood of extreme withdrawal effects even at the 48 hour period. This 
consideration enabled therapy to begin in the first or second week of one’s entrance into 
the treatment center; however, we also balanced the need to have all sessions completed 
before 30 days for any client with a 30-day contract (which comprised approximately 
60% of our sample).  
In line with the issue of timing of the initial assessment and accommodating 30-
day clients, we also discussed the most appropriate length (number of sessions) for 
optimal delivery of the treatment, considering issues related to both efficacy and 
effectiveness. Although we initially wanted to further test the original 6-session manuals 
(that included 2 review maintenance sessions following the 6 sessions) used in the 
Daughters et al. (2008) study, we also noted that we wanted to accommodate the large 
percentage of clients that were only in treatment for 28 to 30 days; the 6-session (plus 
two maintenance sessions) protocol was not able to be administered to clients with 30-
day contract lengths, given the initial delay in beginning treatment due to a) the need to 
control for any lingering effects of detoxification, as well as b) study procedures that 
preceded initiation of treatment (including the initial SCID screening, recruitment, and 
baseline assessment procedures). Weighing the benefits of increased effectiveness and 
optimal applicability to the residential treatment center given the pressure to provide 
brief, time-efficient treatments, we decided to develop a 5-session version of LET’S ACT 





the current sample). The 5-session version did not eliminate any material from the 
original 6-session manual, but rather combined session content of the last three treatm nt 
sessions into two sessions (4 and 5). We viewed this 5-session format to be optimal 
delivery of the treatment; sessions were spaced out maximally over 3 weeks, allowing for 
30-day clients to begin treatment in their 2nd week at the Center and still cover all 
material included in Daughters et al. (2008).  
Lastly, we also discussed the appropriate timing for assessing clinician-rated 
depression, balancing the need to closely track changes in symptomatology, while also 
allowing for sufficient time to pass for the assessment of remission. Someindividuals, 
particularly those with 30-day contracts, only had approximately 3 weeks in between 
their baseline and post-treatment assessments, thus not allowing for a full month to assess 
for MDD remission. In response, we chose to conduct the MDD module of the SCID-IV-
NP and the assessment of clinician-rated depressive symptoms (HAMD) again only at the 
2-week follow up to ensure ample time in between assessments yet still clo ely 
examining any change from baseline.   
Chapter 2: Research Design and Methods 
2.1 Overall Design  
 The current study was conducted at an inner-city residential substance abuse 
treatment program and recruited 58 depressed substance dependent individuals over a 9-
month period. The overall design examined group differences in dropout from the 
substance abuse treatment center and the extent to which treatment affected depression 
(self-reported and clinician-rated) and behavioral activation outcomes (lev l of activation, 





starting the treatment, immediately following the LET’S ACT treatment, and at a 2-week 
follow up for participants who were still in treatment (those with a contract leng h > 30 
days). This design allowed for an examination of the effect of LET’S ACT on substance 
abuse treatment dropout, depression, and behavioral activation.  
2.2. Recruitment  
  
 Participants (n = 58) were recruited from the Salvation Army Harbor Light 
Residential Treatment Center in Northeast Washington, D.C. The center requires 
complete abstinence from drugs and alcohol, with the exception of caffeine and nicotine; 
regular drug testing is provided and any use is grounds for dismissal from the center.
When needed, detoxification from an outside source is required prior to entry into the 
center. Aside from scheduled activities (e.g., group retreats, physician visits), residents 
are not permitted to leave the center grounds during treatment. Although clients at the 
facility often meet criteria for a dual diagnosis, treatment for mental he lth problems 
other than substance use is typically not available, and the treatment center does not have 
a psychiatrist on staff. Clients with psychiatric problems receive substance abuse 
treatment at this center, but off-site health centers are utilized to provide pharmacological 
treatment (~25% of clients). 
 Within the first week of their arrival to the treatment center, all individuals 
entering the center had a screening assessment session in which they were given the 
SCID-IV-NP (First et al., 2001) and the BDI-II (Beck, Steer, & Ball, 1996). Individuals 
who conducted the intake assessments were trained interviewers predominantly 
independent of the current study. Recruitment for the study was based on the initial 





2) DSM-IV diagnosis of past year Substance Dependence as measured by the SCID-IV-
NP (First et al., 2001); 3) DSM-IV diagnosis of Major Depressive Disorder (MDD) 
and/or score ≥ 12 on the BDI-II; 4) complete detoxification as needed prior to entry into 
the center and/or abstinent for at least one week prior to study participation; and 5) have 
the ability to speak and read English sufficiently to complete intervention procedures 
(determined by ability to read BDI-II at intake). Clients were excluded from the study if 
1) they were taking but not stabilized on psychotropic medication (i.e., < 3 months), or 2) 
met diagnostic criteria for current psychotic symptoms (measured by the SCID-IV-NP, 
First et al., 2001).  
  Residents at the treatment center who met initial eligibility requirements based on 
the SCID-IV were approached by a research assistant on the following Friday afternoon 
(no center implemented treatment groups are scheduled for these times). The research 
assistant asked the resident if they would like to participate in a treatment study that 
focuses on their mood. They were told that they would complete a baseline assessment 
session that day that would last about an hour and a half, and then the following three 
weeks they would participate in treatment groups that meet twice a week. Lastly, they 
were told that they would complete an assessment following treatment that will be similar 
to the baseline assessment, and one 2 weeks later if still in treatment. Payment would be 
provided only for the research assessments ($25 for each assessment completed). If 
interested, the participant provided informed consent, and then the baseline session 
commenced which consisted of a packet of questionnaires. If participants declined 
participation (which occurred once during recruitment), they were able to return to 





as to whether or not they had chosen to participate, thereby limiting any appearance of 
coercion to participate. Individuals who agreed to participate in the study signed the 
informed consent and then were assigned a subject number that was listed on all data 
forms. Given issues of reading comprehension, efforts were made to ensure that 
participants understood all facets of the consent form and the study itself, however 
individuals who were unable to read and therefore unable to understand the consent form 
on their own were not included, given that both treatments required written homework 
assignments. The SCID-IV interviewers noted literacy (based on ability to read the BDI-
II), and any individuals unable to read the BDI-II, even if they met all other inclusion 
criteria, were not recruited (n = 4). All assessment sessions were held in private rooms at 
the Salvation Army Harbor Light facility during designated “free time” p riods at the 
center. The center director had provided permission for access to clients evry Friday 
during these times until the study was complete.  
2.3 Procedure 
 Once recruited and consent was provided, participants began the baseline 
assessment in a room at the Center with about 10 large tables. Each participant sat at a 
separate table when completing the baseline assessment. The baseline asssment 
consisted of a battery of self-report measures assessing demographics, drug use severity, 
depressive symptomatology, and behavioral activation (activity level, enjoyment and 
reward from activities). A proctor was in the questionnaire room at all times to provide 
instruction and answer any questions the participants have. Following completion of the 
interviews and self-report measures, participants signed two receipts (one for the 





residential treatment. Their receipt listed instructions to obtain the gift cards, which 
involves calling research staff and providing a mailing address where we could send the 
gift cards. Names and addresses were verified against the copy of the receipt w  kept 
from the assessment. Gift cards were only mailed following discharge so staff did not 
know if individuals have chosen to participate. Further, the payment receipts only 
included names and no number so that client name and responses could not be matched 
by any study personnel.  
 Following the baseline, subjects were randomized to either LET’S ACT or SC 
with treatment beginning the following Monday or Tuesday to ensure ample group size 
but also limit delay to participation. Following completion of the baseline session, all five 
therapy sessions were scheduled across the next 3 weeks of the participant’s stay in the 
center, and the groups (SC and LET’S ACT) consisted of 3-5 participants. Groups 
occurred during the morning timeslots, and thus (with the exception of Fridays) clients 
were taken out of their scheduled groups for one hour. This was consistent across 
therapists, given that all therapists ran groups during the 9 am to 11 am timeslots. The 
post-treatment assessment occurred the Friday afternoon after all tratment sessions had 
been completed. For participants who were still in the center 15 days following the post-
assessment, a similar assessment was given as a 2-week follow up. At this assessment, 
clinician-rated depression ratings were administered (using the HAMD) and MDD 
remission was also assessed by a trained SCID interviewer. The research assistants who 
helped with conducting the assessments (with the exception of Ms. Magidson who did the 
initial treatment assignment) were blind to treatment group. Participants were also paid 





manner as was performed for the baseline. No payment was given at the 5 treatment 
sessions; total possible payment was $75.  
2.4 Overview of Treatment 
 In this study, groups were randomized either to LET’S ACT or SC, and treatment 
was delivered in five sessions over a 3-week period. Each of the treatment sessions lasted 
approximately 1 hour. A description the treatment is presented below.  
2.4.1 LET’S ACT 
 LET’S ACT is based on the empirically validated Behavioral Activation 
Treatment for Depression (BAT-D; Lejuez, Hopko, & Hopko, 2001) and was modified to 
accommodate the needs and lifestyles of a substance using population currently receiving 
inclient substance abuse treatment. The vocabulary within the LET’S ACT manual was 
simplified to be more comprehendible to those with limited formal education background 
and/or cognitive deficits resulting from acute and more long-term pharmacological 
effects of repeated drug use. Complex concepts and forms were eliminated, replaced, or 
modified. To further accommodate treatment compliance and homework completion, 
clients were given pocket sized client manuals which include daily monitoring frms, 
daily goal sheets, life area assessments, and additional note pages. Attendance and 
completion of homework assignments was recorded at the start of each treatment sessio  
for all clients.  
 Specifically, treatment included five sessions over a three-week period and was 
provided in small group format, with each group consisting of 3-5 clients. To address 
both the early and late stages of substance abuse treatment, earlier sessions focused on 





residential treatment discharge planning and goals. The first session consisted of an 
introduction of the treatment rationale, life values and goals exercises, and homework 
was assigned to self-monitor current activities and daily moods. The second session
reviewed the content of the first and the homework, and moved onto identifying activities 
to fulfill the life area goals set in the first session. Behavioral contracts were also 
introduced in this session. Session three focused on establishing daily and weekly goals, 
and daily and weekly goal setting in the client manual was the homework assigned 
throughout the remainder of treatment. Finally, sessions four and five focused on 
reviewing daily and weekly goal setting exercises, integrating new activities into daily 
and weekly goals, and discussing a post-treatment plan.   
2.4.2 Supportive Counseling (SC) 
 To control for the non-specific elements of therapist contact and additional 
treatment group involvement, the other half of the clients received SC, which also 
consisted of five group sessions over 3 weeks. This treatment did not follow a clearly 
defined theoretical model and can be best described as unconditional support and 
reflective listening in response to any issues the participant brought to session, which has 
been utilized as a control condition in other treatment outcome studies specific to 
substance abuse (e.g., Azrin et al., 1994) and depression (Manne et al., 2007; Thase et al., 
2000). For the purposes of this study, SC specifically avoided behavioral activation 
techniques. Although no therapeutic content for LET’S ACT was added into SC, features 
such as the use of a manual and journal writing homework forms were utilized to control
for the effects of homework and manualization in LET’S ACT. Attendance and 





session to control for the effects of recording such information.  
2.5 Therapist adherence, fidelity, and competence 
 Four therapists were cross-trained in LET’S ACT and SC by Dr. Daughters, and 
all therapists administered both treatments to control for therapist effects. Therapists were 
randomly assigned treatment groups by the research coordinator, Ms. Magidson, ba ed on 
a set therapist rotation but were also counterbalanced across groups. The administr tion 
of treatment was completely separate from research assessments. Therapists were 
supervised by Dr. Lejuez at a weekly supervision meeting open to all lab members, and 
Dr. Daughters was also available for consultation as needed for study therapists. 
Therapist manuals developed by Dr. Daughters, Dr. Lejuez, and Ms. Magidson were used 
at all times to ensure standardization of treatment delivery. Therapists were provided 
feedback on their sessions and were given additional supervision when indicated. All 
therapists completed therapist adherence forms, which outlined the components of the 
manual for each session for both LET’S ACT and SC treatment conditions. After each 
session, therapists completed the adherence forms and provided them to Ms. Magidson 
weekly. All therapy sessions were audiotaped, and therapists uploaded their session 
MP3’s into a study folder on a shared drive. MP3 files were saved as the group number 
and session number, thus protecting participants’ confidentiality without having any 
identifying information linking the files to them. Ms. Magidson listened to 20% of 
audiotaped sessions (there were 80 sessions in total for the 16 groups), listening to at least 
two treatment sessions of each treatment type per therapist (16 sessions total). For e ch 
session, Ms. Magidson used the therapist adherence forms to assess competency with the 





There were separate forms for SC and LET’S ACT, and a key issue focused on when 
listening to the recorded sessions was the avoidance of directive feedback and behavioral 
activation techniques specifically in the SC condition. When any therapist drift from the 
protocol was detected, therapists were given feedback during supervision. Participants’ 
adherence to treatment was assessed by their attendance at program sessions and 
homework completion using forms developed for the LET’S ACT and SC protocols that 
were filled out by the therapist following each session. This was done for both conditions 
to control for any effects of recording attendance and homework completion.  
2.6 Participants 
The final sample consisted of 58 participants who met inclusion criteria for the 
study. A total of 4 participants who met all inclusion criteria but were not literate 
(assessed at BDI-II administration at the screening) were not recruited for the study, and 
1 participant who was approached for the study refused. 16 treatment groups were 
conducted with 3-5 participants in each group. Groups were conducted from November 
1st, 2008 through July 27th, 2009 (see Figure i for a consort diagram of study recruitment 
and retention).  
As shown in Table 1, the mean age of the sample was 44.78 (SD = 9.39), ranging 
in age from 24-65 years. Men comprised 65.5% of the sample (n = 38), and 89.7% 
identified as African American (n = 52). In terms of education, 75.9% reported having a 
high school education/GED or less (n = 44), and 24.1% reported having more than a high 
school diploma or GED (e.g., a few years of college or technical school; n = 14). With 
regard to income and employment, 82.1% made less than $10,000 per year (n = 47), and 





With regard to marital status, 81.1% of the sample was single and never had been marri d 
(n = 47). Regarding treatment characteristics, 53.4% were voluntarily attending treatment 
(n = 31) as opposed to being court-mandated (46.6%; n = 27); 59% of the sample had a 
30-day contract of residential treatment ( = 34), 31% had a 60-day contract (n = 18), and 
10.3% had >60 day contract (90 or 180 days; n = 6).  
In terms of clinical variables (see Table 2), 60.3% of the sample met criteria for 
current MDD and the mean BDI-II score was 18.89 (SD = 9.41); 71% of the sample also 
met criteria for recurrent MDD. Regarding psychotropic medication, 53.4% were 
stabilized on psychotropic medication at baseline, and 46.6% were not taking any 
psychotropic medications. In terms of the most prevalent drug dependencies (over 5% of 
the sample meeting criteria), 50.9% of the sample met criteria for current alcohol 
dependence, 46.6% of the sample met criteria for current cocaine dependence, 24.1% 
current opioid dependence, 8.8% met criteria for current marijuana dependence, and 
47.4% of the sample met criteria for current dependence for two or more drug classes. 
Lastly, with regard to other comorbid Axis I and II diagnoses, we examined the 
prevalence of any comorbid conditions in which > 5% of the sample met criteria, which 
included Post-traumatic Stress Disorder (PTSD), Generalized Anxiety Disorder (GAD), 
Borderline Personality Disorder (BPD), and Antisocial Personality Disorder (ASPD). 
With regard to comorbid anxiety, 21.8% of the sample also met criteria for current PTSD 
and17.5% met criteria for current GAD. In terms of Axis-II comorbidity, 36.8% met 
criteria for BPD, and 49.1% met criteria for ASPD. See Table 2 for the ates of all 






 Measures were organized into four domains: (a) demographics, baseline substance 
use, and comorbid psychopathology to be used as potential covariates in analyses; (b) 
depressive symptomatology, which was used to examine specific symptom-level changes 
in depression; (c) behavioral activation measures of activity level and environmental 
reinforcement to test treatment effect on behavioral activation; and (d) therapy-related 
factors to identify additional considerations for the optimal administration of treatment.  
Table 20. Descriptions of assessment measures in four domains 
 
Domain Measure Description 
Demographics, Substance 
Use, and Psychopathology 
Demographics Questionnaire 
Baseline 
Basic information on age, gender, race, education 
level, marital status, and total household income 
Legal Status 
Baseline 




Diagnostic information (Axis I Psychopathology, 
BPD and ASPD) 
Medication Questionnaire 
Baseline 
Frequency, dosage, and type of various 
medications, including psychotropic, non-
psychotropic, and over-the-counter medication 
Depressive Symptomatology 
HAMD 
Screening, 2-week follow up 
Clinician-rated severity of depressive symptoms 
BDI-II  
Screening, Post, 2-week follow up 
Self-report assessment of depressive symptoms 
Behavioral Activation: 




Baseline, Post, 2-week follow up 
Self-report assessment designed to measure 
increases in BA; 4 subscales include activation, 
avoidance/rumination, and work/school and 
social impairment  
EROS 
Baseline, Post, 2-week follow up 
Assessment of reward and enjoyment derived 
from activities; environmental reinforcement 
Therapy-related factors 
Program Evaluation Form 
Post 
Satisfaction rating of residential treatment 
CMR 
Baseline 
Assessment of treatment motivation, readiness, 





Treatment center dropout 
Baseline to post 
Dropout rates of LET’S ACT and SC 
participants in first 30 days of treatment, date 





2.7.1 Demographics, Substance Use, and Psychopathology 
 
 Demographic Questionnaire. A short self-report questionnaire was administered 
at baseline to obtain age, gender, race, education level, marital status, and total household 
income.  
The Legal Status Form provided information as to whether the participant’s 
admission to substance abuse treatment center was voluntary or court-mandated. Furth r, 
the form was composed of additional questions pertaining to one’s past arrest and 
conviction history, type of arrests/convictions, and length of time spent incarcerated. 
Structured Clinical Interview for DSM-IV (SCID-NP, non-client version; First, 
Spitzer, Gibbon, & Williams, 1995). Diagnostic inclusions/exclusions and lifetime 
prevalence of Axis I diagnoses (including but not limited to MDD, alcohol dependence, 
non-alcohol substance dependence, and current psychosis) were determined at screning 
using the SCID-NP, which has demonstrated high reliability and validity in substance 
using samples (Kranzler et al., 1996; Spitzer, Williams, Gibbon, & First, 1989). BPD and 
ASPD were the only two Axis-II conditions assessed. Psychosis, current MDD, and 
substance dependencies were used for study inclusion criteria, and other Axis I and II 
comorbidities were used as potential covariates in analyses. Lastly, the MDD module of 
the SCID was also administered at the 2-week post-treatment assessment to assess for 
MDD remission (see Appendix for results).  
Medication Questionnaire. To determine if psychotropic or other medication may 
influence the expected results, we collected data from the subjects by simplasking 
which medications they had been taking currently (if any), how long they had been taking 





dichotomous variable: 1) psychotropic medication or 2) any other over-the-counter 
medications or treatments for other medical conditions. Clients were excluded if not 
stabilized on psychotropic medication for > 3 months (this is also asked at the intake 
interview). Any changes in medications were also assessed at post assessments. 
2.7.2 Depressive Symptomatology 
 
  The Hamilton Rating Scale for Depression (HAMD; Hamilton, 1960) was used as 
a clinician assessment of depressive symptom severity. This 21-item scale includ s 
questions pertaining to libido, energy, weight, and appetite changes. Scores are combined 
into a single total score, and the measure has been shown to have strong 
divergent/convergent validity and reliability. The HAMD was administered at screening 
with the SCID interview and at the 2-week follow up with the MDD module of the SCID. 
  The Beck Depression Inventory-II (BDI-II; Beck, Steer, & Ball, 1996) was used to 
assess self-reported depressive symptoms. The BDI-II is a 21-item inventory that assesses 
the severity of depressive symptomatology.
 
Each item is rated on a 0-3 scale with 
summary scores ranging between 0 and 63. The BDI-II has consistently shown strong 
reliability and validity, as well as high concurrent validity with HAMD ratings (Beck, 
Steer, & Carbin, 1988). The BDI-II was administered at screening with the SCID and at 
the two subsequent assessments.  
2.7.3 Behavioral Activation: Activity Level and Environmental Reinforcement 
 The Behavioral Activation for Depression Scale (BADS; Kanter, Mulick, Busch, 
Berlin, & Martell, 2007) was used to assess specific changes in activity level. The BADS 
was specifically designed to assess when and how clients become activated over the 





depression. Specifically, participants are asked to state how true a list of 25 statements is 
for him/her in the past week, and answers are provided on a 7-point scale ranging from 0 
(not at all) to 6 (completely). The BADS has four subscales. “Activation” is made up of 7 
items that assess “goal-directed activation” and completion of scheduled activities (for 
example, “I engaged in a wide and diverse array of activities” and “I did something that 
was hard to do but it was worth it”). The “Avoidance/Rumination” subscale consists of 8 
items and is aimed at measuring avoidance behaviors that may be interfering with 
activation (e.g., “I did things to avoid feeling sadness or other painful emotions,” “I tried 
not to think about certain things”), and the last two subscales examine specific domains 
of impairment, including “Work/School Impairment” and “Social Impairment.” Both 
contain 5 items and measure behaviors directed toward the accomplishment of important 
life goals (e.g., “I took time off of work, or other responsibilities simply because I was 
too tired or didn't feel like going in” and “I was withdrawn and quiet, even around people 
I know well”). In addition to the four subscales, a total score reflects overall “behavioral 
activation” which encompasses overall activity level, levels of avoidance behaviors, as 
well as goal-directed activity and social/occupational impairment. Higher scores indicate 
higher levels of behavioral activation (and lower levels avoidance/rumination, 
impairment for the subscales). The BADS has been demonstrated to have good factor 
structure, internal consistency, test-retest reliability, and construct and predictive validity 
(Kanter et al., 2007; 2008). The BADS was administered at all assessment time points. 
  The Environmental Reward Observation Scale (EROS; Armemento & Hopko, 
2007) was used to compare levels of environmental reinforcement across treatment 





contingent positive reinforcement, such that items are intended to measure “increased 
behavior and positive affect as a consequence of rewarding environmental experiences,” 
as well as the degree to which an individual is obtaining positive reinforcement from the 
environment as a result of his/her behavior. The measure asked participants to rate the 
degree in which they agree with each statement (1 = strongly disagree to 4 = strongly 
agree) and examples of items include: “In general, I am very satisfied with the way I 
spend my time” and “I wish that I could find more hobbies that would bring me a sense 
of pleasure.” Reliability and (divergent/convergent) validity indices for the EROS are 
strong (Armemento & Hopko, 2007). The EROS was administered at all assessment time 
points.  
2.7.4 Therapy-related factors 
  The Program Evaluation Form is an 8-item self-report measure assessing 
participant’s perceived quality and satisfaction of treatment (LET’S ACT or SC). 
Questions include “To what extent has this program met your needs?” and “How would 
you rate the quality of the service you received?” Answers are provided on a 4-point 
Likert scale; participants’ ratings can be seen as reflecting overall satisfaction with the 
LET’S ACT or SC treatment programs.  
  The Circumstances, Motivation, Readiness Scale (CMR; De Leon, Melnick, 
Kressel, & Jainchill, 1994) was used to assess treatment motivation. The CMR is an 18-
item factored version of the 42-item CMRS used in residential substance abuse treatment 
samples. The self-report measure employs Likert-type items rated on a 5-point scale from 
“strongly disagree” to “strongly agree” and all questions are at a 3rd grade reading level. 





motivation (intrinsic pressures regarding the need to change), and readiness (perceived 
need for treatment). In addition to the subscale scores, a total CMR score assessed th  
individuals’ overall potential to enter and remain in substance abuse treatment. The 
measure has demonstrated strong reliability, with Cronbach alpha values ranging from 
.60 on subscales to .85 for the total score. 
  The Working Alliance Inventory (WAI; Horvath & Greenberg, 1989) was used to 
assess therapeutic alliance and was administered at the post-treatment session. The WAI 
is a 36-item measure composed of items reflecting desirable aspects of the therapeutic 
relationship, and each item is assessed on a 7-point Likert scale ranging from 1 (never) to 
7 (always), higher scores indicating a more positive therapeutic alliance.  
Treatment Dropout was calculated using two indices, one continuous and one 
categorical. First, we had a dichotomous index of whether an individual has dropped out 
before the completion of 30 days; the second was days missed before the completion of 
30 days. LET’S ACT and SC therapists provided the research coordinator, Ms. 
Magidson, with a list of any subject numbers of participants that dropped out of the 
treatment center and reasons for dropping out. This information was cross-checked with 
Center staff, and the date of dropout was also confirmed with the Center intake 
coordinator. Treatment dropout was classified as two types of dropout: dropout due to 
noncompliance with the residential treatment center agreement (e.g., rule violations, 






Chapter 3: Results 
To address the primary study hypotheses, that participants who received LET’S 
ACT would evidence greater reductions in substance abuse treatment dropout, greater 
reductions in depressive symptoms, and greater increases in behavioral activation, a 
number of steps were undertaken and are outlined below. The first step included a 
comparison of the two groups on all baseline demographic and clinical variables to 
ensure baseline equivalence of groups. Next, we identified a set of potential covariates 
for each analysis based on literature reviews of theoretically-relevant variables, which 
included variables such as basic demographic information including age and gender,
contract type, court-mandated status, current class of drug dependencies, whether 
someone was dependent on multiple drugs, use of psychotropic medication as well as any 
comorbid anxiety disorder or Axis-II disorder. The population we recruited often has 
numerous comorbid Axis I and II conditions (including numerous drug dependencies), 
and thus to maximize effectiveness of the current trial yet still maintain internal validity 
we chose to consider any of these comorbid diagnoses as covariates if related to the main 
outcome for each analysis, as these variables could potentially impact all three main 
outcomes. Thus, for each analysis, we examined the relationship between the theory-
driven potential covariates and the main outcome (using chi square analyses for two 
categorical variables, ANOVAs for one categorical and one continuous variable, and 
correlations for two continuous variables). Any variable significantly related to the main 
outcome (p < .05) was included as a covariate in the analysis of that main outcome.  
To address the first study hypothesis, comparing rates of substance abuse 





proportional hazards survival regression analysis (to predict days to dropout) were used. 
For the second and third hypotheses, to examine differential effects of treatment on 
depression and behavioral activation, generalized estimating equations (GEE; Liang & 
Zeger, 1986; Zeger & Liang, 1986) analyses were utilized for variables assessed at all 3 
time points (BDI-II, BADS, EROS). GEE allows for inclusion of either categorical or 
continuous independent variables and is advantageous when examining multiple 
observations that are correlated across time. In all GEE analyses, we center d our linear 
time variable for consistency and clarity of interpretation. Clinician-rated depressive 
symptoms (HAMD) were only assessed at baseline and the 2-week follow up1, thus for 
this main outcome with two time points, only repeated measures ANOVAs were used. 
Lastly, to supplement GEE analyses that examined change over the 3 time points, we also 
utilized repeated measures ANOVA analyses to examine changes in BDI-II, BADS, and 
EROS scores from pre- to immediately post-treatment, when the majority of our sample 
was assessed (any client with a 30-day contract was not still in treatment to receive a 2-
week follow up assessment).  
3.1 Equivalence of Groups 
LET’S ACT and SC were compared to ensure equivalence of groups on relevant 
variables such as demographics (Table 1), clinical variables such as court-mandated 
status, treatment motivation/readiness, contract length, class of drug dependency, and any 
comorbid diagnoses (Table 2), as well as baseline levels of the outcome variables, such as 
baseline depressive symptoms and MDD status, and baseline levels of behavioral 
activation (Table 3). Tables 1, 2, and 3 provide detailed information on the descriptive 
                                                
1 We also assessed MDD remission at the 2-week follow up with the HAMD; see Appendix for the analysis 
predicting MDD status at the 2-week follow up. This was considered a secondary analysis given the small





information for all variables for the total sample and by group. Additionally, group 
differences for all variables were assessed using ANOVAs for continuous variables and 
chi-square tests for categorical variables. As shown in Tables 1, 2, and 3, the only 
variable that was significantly different between groups was prevalence of alcohol 
dependence, such that there was a significantly higher rate of individuals that me criteria 
for alcohol dependence at baseline in the SC group (69%) compared to the LET’S ACT 
group (32.1%; χ2  (1) = 7.73). There were no differences across the two treatment 
conditions on any of the other demographic or baseline clinical variables (all p > .05). 
We then examined the relationship between alcohol dependence and our main outcome 
variables (treatment dropout yes/no, days to dropout, HAMD, BDI, BADS, and EROS 
scores) to identify any relationship in which alcohol dependence was related to the main 
outcome variable. Alcohol dependence was not shown to be significantly related to any 
of our main outcome variables (all ps > .15), and thus was not included as a covariate in 
analyses.  
3.2 Comparison of 30-day vs. 60, 90, and 180 day contracts 
We also examined any differences between individuals with a 30-day contract and 
those with longer-term contracts to examine the potential for biased results at the 2-week 
follow up if significant differences were to exist between those who are excluded from 
the 2-week follow up assessment given their 30-day contract status. All baseline 
demographic and clinical variables used to compare group differences (LA vs. SC) were 
included. The only significant differences between contract length types were prevalence 
of alcohol dependence and BPD diagnoses. With regard to alcohol dependence, 63.6% of 





term clients (χ2  (1) = 5.11, p < .02). With regard to BPD, there was a significantly greater 
proportion of the longer-term contract participants that met criteria for BPD (54.2%) 
compared to those with 30-day contracts (37.5%; χ2 (1) = 4.24, p < .04), which further 
suggests that we cannot assume the 30-day clients were more or less severe than th  
longer-term clients2.  Moreover, there were no significant differences between the 
baseline levels of any of the main outcome variables when comparing individuals with 
30-day vs. longer term contract lengths (all ps > .30). See Tables 15-17 for results.  
3.3 Therapy-related factors  
 Before analyzing our main outcomes, we examined group differences in therapy-
related factors at post-treatment, such as treatment satisfaction and working alliance. As 
shown in Table 6, there were no differences between groups on treatment satisfaction or 
working alliance (all ps > .60).   
3.4 Primary Hypothesis 1: Treatment dropout 
3.4.1 Logistic Regression Predicting Categorical Dropout 
The first step in examining the relationship between treatment condition and 
dropout from the residential treatment center was to first examine any relevant baseline 
variables that may be related to treatment dropout. To provide further descriptive data on 
our sample and factors associated with substance abuse treatment dropout, all variables 
discussed previously when examining treatment group differences (demographic, 
clinically relevant variables, baseline levels of the main outcomes of depression and 
behavioral activation) were examined in relation to treatment dropout (categorical status 
                                                
2 For all analyses that included the 2-week follow up (all GEE analyses and the HAMD repeated measures 
ANOVA), we also conducted the analyses with alcohol dependence and BPD as covariates. The inclusion 
of these two variables as covariates did not affect r sults; all significant results remained significant, and all 





of dropout from center in first 30 days). ANOVAs were used for continuous variables 
and chi-square tests for categorical variables. The only variable significantly related to 
treatment dropout was being on psychotropic medication (yes/no), such that participants 
who dropped out of the center were significantly more likely to be taking psychotropic 
medication (χ2 (1) = 8.08, p = .004). In fact, all participants (n = 8) who dropped out of 
the treatment center were stabilized on psychotropic medication at the baseline 
assessment. See Tables 12, 13, and 14 for the relationships between all other baselin  
demographic and clinical variables in relation to treatment dropout.   
 In line with our first hypothesis (outlined in 1.7) that participants in LET’S ACT 
would evidence significantly lower rates of residential treatment dropout as compared to 
those in SC, we conducted an intent-to-treat logistic regression analysis predicting 
dropout from residential treatment in the 30-day study period (Dropout = 1, No dropout = 
0).3 Psychotropic medication status was not utilized as a covariate in the subsequent 
analysis given that it acted as a constant in its relationship with treatment dropout 
(because all participants who dropped out were on psychotropic medication). Thus, in the 
first step we entered our independent variable: treatment condition (LA = 1, SC = 0). The 
analysis revealed a main effect for treatment condition, such that individuals in the 
Supportive Counseling were more likely to dropout of treatment compared to those in the 
LET’S ACT condition (OR = 8.91, CI = 1.02-77.91, p < .05). See Table 5 for results of 
this analysis.  
                                                
3 Of note, we also conducted the same analyses for treatment dropout (both the logistic regression and cox 
proportional hazards survival analysis) using a completer sample and found no differences in results; 
specifically all significant results remained significant and all nonsignificant results remained 
nonsignificant. We chose to only report the intent-to- reat analysis given its consideration as the “gold 





3.3.2 Cox Proportional Hazards Survival Regression Analysis Predicting Days to 
Dropout 
As a richer analysis of dropout using continuous assessment, we examined the 
effects of treatment condition on days to dropout using an intent-to-treat Cox proportional 
hazards survival regression analysis predicting days to dropout from the center (in th  30 
day period). First, we examined what baseline variables (same as discussed above for 
logistic regression) were associated with days to dropout to again give a richer 
descriptive picture of our sample and the factors associated with the number of days in 
treatment. All categorical variables (demographic information, baseline diagnoses, 
contract information) were analyzed in relation to days to dropout using ANOVAs. 
Results of the ANOVA indicated that no variables were significantly related to days to 
dropout (all ps > .2). Baseline continuous variables (including age, baseline levels of 
main outcome variables) were examined using correlations with the variable of days to 
dropout. Results indicate that the baseline BADS total score (r = .27, p = .04), the 
Activation subscale (r = .27, p = .04), and baseline EROS scores (r = .26, p = .05) were 
the three variables significantly related to days to treatment dropout, however no 
demographic or baseline variables that would potentially be included as a covariate in the 
analysis (i.e., age, gender, court-mandated status, contract type, current class of drug 
dependencies, dependency on multiple drugs, comorbid anxiety or Axis-II disorders) 
were significantly related to days to dropout.  
In the first step of the Cox proportional hazards survival regression analysis 
predicting days to dropout, we entered treatment condition (LA = 1, SC = 0). The 





a shorter number of days to treatment dropout compared to LET’S ACT (hazards ratio = 
7.92, CI = .98-64.57, p = .05). Specifically, SC predicted approximately an eightfold 
increase in the likelihood of treatment dropout on any given day within the 30-day 
period. See Table 6 for results.  
3.5 Primary Hypothesis 2: Depression outcomes 
 To test the second hypothesis, whether participants in LET’S ACT vs. SC 
evidenced a greater reduction in depressive symptoms over time, we conducted analyses 
on both self-reported depressive symptoms (BDI-II) and clinician-rated depressive 
symptoms (HAMD).  See Figure 1 for a consort diagram of recruitment and retention 
throughout the study, which includes the sample size for each group at each assessment 
time point for the analyses conducted in the remaining sections. 
3.5.1 Self-reported depressive symptoms: GEE analysis 
First, we examined change in self-reported depressive symptoms over time using 
the BDI-II at three assessment time points: baseline, post-treatment, and 2-week follow 
up. We used GEE analyses to capture change over time in depressive symptoms using all 
three time points. Before examining group differences, we first examined which baseline 
variables were significantly related to change in BDI scores over time to id ntify 
potential covariates for analyses from our theory-driven set of potential covariates (age, 
gender, current class of drug dependencies, dependency on multiple drugs, use of 
psychotropic medication, as well as any comorbid anxiety disorder or Axis-II di order). 
For categorical baseline variables, we examined the relationships using ANOVAs, and 
for continuous baseline variables, we used correlations with the variable of average BDI-





II score over time was sex, such that men evidenced a greater decrease in BDI-II scores 
compared to women. Men had a mean BDI-II score of 18.52 at baseline (SD = 8.83), and 
their average BDI-II score over the three time points was 15.17 (SD = 9.09). Women had 
a mean BDI-II score of 19.68 (SD = 11.54) and their average BDI-II score over the three 
time points was 17.02 (SD = 10.47).  
Gender was included as a covariate in all analyses. First, we tested the main 
effects of time and treatment, and then we tested the interaction between treatment 
condition and time to examine whether there was a significant difference in the rate of
change in BDI-II score in the LET’S ACT vs. SC group across the 3 time points. In the 
final model, which included time, gender, treatment, and the treatment x time interaction, 
the main effect of time was significant (B = -5.58, SE = 1.21, p < .001), demonstrating 
that there was a significant decrease in depressive symptoms over time for the entire 
sample. There was not a significant main effect for gender or treatment, but the treatment 
x time interaction was significant in the final model (B = -3.49, SE = 1.52, p = .02), 
indicating that individuals in the LET’S ACT group evidenced a significantly greater 
reduction in BDI-II score over time as compared to those in SC (See Table 7).  
3.5.2 Repeated measures of pre- to post-treatment changes in self-reported depressive 
symptoms 
To supplement GEE analyses that examined change over the 3 time points, we 
also utilized repeated measures ANOVA analyses to examine changes in self-reported 
depressive symptoms (BDI-II) from pre- to post-treatment, given the larger sample size at 
these two time points. First, we examined the relationships between relevant baseline 





covariates to include in the analysis (again considering age, gender, current lass of drug 
dependencies, multiple drug dependencies, use of psychotropic medication, as well as 
any comorbid anxiety disorder or Axis-II disorder). Two baseline variables in our set of 
potential covariates were found to be significantly related to change in BDI-II from pre- 
to post-treatment: sex and age, such that men were more likely to evidence a greater 
change in depression from pre- to post-treatment, as well as those who were young r.  
We included gender and age as covariates, and we tested the interaction between 
treatment condition and time to examine whether there was a significant difference in the 
rate of change in BDI-II score from pre- to post-treatment in the LET’S ACT vs. SC 
group. We used repeated measures ANOVAs with treatment group as the betwe n 
subjects factor and scores on the BDI-II as the within subject factor. Results indicated 
that a group x time interaction was not significant between the two groups on the BDI-II 
(F(1, 44) = 0.001, p =.99, η2= 0). See Table 8 for results of the group x time interaction 
and Tables 18 and 19 for means of BDI-II scores at baseline and post-treatment point by 
group.4  
3.5.3 Clinician-rated depressive symptoms  
Next, we examined clinician-rated depressive symptoms using the HAMD. The 
clinician reports (HAMD and SCID-IV-NP) were only conducted at baseline and the 2-
week follow up to ensure ample time in between clinician assessments. To assess change 
in HAMD from pre- to post-treatment, we utilized repeated measures ANOVAs (this is 
the only analysis for the HAMD because GEE was not conducted with only two available 
time points). 
                                                
4 Of note, we also conducted both analyses without including covariates in the model and obtained the 






First, we examined the relationships between relevant baseline variables and the 
change in HAMD scores from baseline to the 2-week follow up to identify potential 
covariates to include in the analysis (again considering age, gender, currentlass of drug 
dependencies, multiple drug dependencies, use of psychotropic medication, as well as 
any comorbid anxiety disorder or Axis-II disorder). Of these variables, only being on 
psychotropic medication (dichotomous variable) at baseline was significantly related to 
change in HAMD score from baseline to the 2-week follow up ( p = .003), such that 
being on medication at baseline was related to a greater change in HAMD score from 
baseline to the 2-week follow up (F(1, 18) = 6.82, p = .02).  
In all analyses related to change in HAMD, we included use of psychotropic 
medication as a covariate. First, we tested the interaction between treatment condition 
and time to examine whether there was a significant difference in the rate of change in 
HAMD scores from baseline the 2-week follow up in the LET’S ACT vs. SC group. We 
used repeated measures ANOVAs with treatment group as the between subjects factor 
and scores on the HAMD as the within subject factor. Results indicated a significant 
group x time interaction, such that individuals in the LET’S ACT group demonstrated 
significantly greater reductions in HAMD scores from baseline to the 2-w ek follow up 
compared to the Supportive Counseling condition (F(1, 17) = 4.30, p = .05, η2= .20). 
Next, we did a follow up probe of the interaction. In the LET’S ACT group, repeated 
measures analyses indicated a significant decrease in HAMD scores from baseline to the 
2-week follow up (F(1, 13) = 10.79, p = .006, η2 = .45). In the Supportive Counseling 





scores (F(1, 5) = .132, p = .732, η2 = .03). See Table 8 for results and Tables 18 and 19 
for means of HAMD scores at baseline and 2-week follow up by group.5 
3.6 Primary Hypothesis 3: Behavioral Activation outcomes  
 To examine the third primary hypothesis, is LET’S ACT associated with greater 
increases in behavioral activation over time compared to Supportive Counseling, we 
utilized GEE analyses to examine changes in two measures of behavioral act vation over 
the three assessment time points. As described previously, the BADS assesses overall 
levels of activation, while the EROS assesses reinforcement derived from activities. Both 
measures were administered at all three assessment time points, and separate GEE 
analyses were used to capture change over time for each measure.  
3.6.1. Overall levels of activation: GEE analysis 
Starting with the BADS, we first examined the relationships between baseline 
demographic/clinical variables and change in BADS over the three time points to den ify 
potential covariates to include in analyses. For all categorical baseline variables, we used 
ANOVAs, and for all continuous baseline variables, we used correlations. No variables 
we considered as potential covariates were significantly related to change in BADS over 
the three time points (age, gender, current class of drug dependencies, dependency o  
multiple drugs, use of psychotropic medication, as well as any comorbid anxiety disorder 
or Axis-II disorder). 
Next, we tested the main effects of time and treatment, and then we tested the 
interaction between treatment condition and time to examine whether there was a 
significant difference in the rate of change in BADS score in the LET’S ACTvs. SC 
                                                
5 We also conducted the same analyses without including use of psychotropic medication as a covariate and 





group across the 3 time points. In the final model, which included time, treatment, and 
the treatment x time interaction, the main effect of time was significant (B = 10.52, SE = 
4.83, p < .05), demonstrating that there was a significant increase in levels of activation 
over time for the entire sample. There was not a significant main effect for treatment or a 
significant treatment x time interaction (ps > .3). See Table 9 for results. 
3.6.2 Environmental reinforcement derived from activities: GEE analysis 
Next, for the EROS analysis, we first examined the relationships between bas line 
demographic/clinical variables and change in EROS over the three time points to identify 
potential covariates to include in analyses. No potential covariates were significantly 
related to change in EROS score over time (the same set of theory-driven covariates 
considered above for BADS were utilized for EROS).   
Next, we tested the main effects of time and treatment, and then we tested the 
interaction between treatment condition and time to examine whether there was a 
significant difference in the rate of change in EROS score in the LET’S ACT vs. SC 
group across the 3 time points. In the final model, which included time, treatment, and 
the treatment x time interaction, the main effects of time and treatment were not 
significant (ps > .2), and there was not a significant treatment x time interaction (B = -.72, 
SE = 1.16, p = .53). See Table 10 for results.   
3.6.3. Repeated measures of pre- to post-treatment changes in behavioral activation  
To supplement GEE analyses that examined change in behavioral activation 
measures over the 3 time points, we also utilized repeated measures ANOVA analyses to 
examine changes in behavioral activation (both the BADS and the EROS) from pre- to 





3.6.4. Repeated measures of pre- to post-treatment changes: BADS 
First, we examined the relationships between relevant baseline variables and the 
change in BADS from pre- to post-treatment to identify potential covariates to include in 
the analysis (again considering age, gender, current class of drug dependencies, multiple 
drug dependencies, use of psychotropic medication, as well as any comorbid anxiety 
disorder or Axis-II disorder). Analyses indicated that no potential covariates were 
significantly related to change in BADS score from pre- to post-treatment (all ps > .2). 
Next, we tested the interaction between treatment condition and time to examine 
whether there was a significant difference in the rate of change in BADS scores fr m pre- 
to post-treatment in the LET’S ACT vs. SC group. We used repeated measures ANOVAs 
with treatment group as the between subjects factor and scores on the BADS as the 
within subject factor. Results indicated a group x time interaction existed between he 
two groups on the BADS (F 1, 46) = 5.19, p <.05, η2 = .1), such that LET’S ACT 
participants evidenced significantly greater increases in behavioral activation compared 
to those in the Supportive Counseling condition (see Table 8). Next, we conducted a 
follow up probe of this interaction to test for the main effects by group.  For the LET’S 
ACT group, repeated measures analyses indicated a significant increase in BADS scores 
from pre- to post-treatment (F(1, 27) = 15.66, p < .001, η2 = .37). In the Supportive 
Counseling group, repeated measures analyses did not indicate a significant change in 
BADS scores from pre- to post-treatment (F(1, 19) = .02, p = .89, η2 = .001). See Tables 
18 and 19 for the means of baseline and post BADS scores by group6.  
                                                
6 We also conducted the same analyses for each BADS subscale. Results indicated a treatment x time 
interaction only on the Social Impairment (SI) subscale (F(1, 46) = 6.2, p < .05, η2 = .12). A follow-up 
probe demonstrated a significant reduction in SI from pre- to post-treatment only in the LET’S ACT 





3.6.5. Repeated measures of pre- to post-treatment changes: EROS 
We conducted the same analyses for the EROS to capture changes in reward 
associated with activities. First, we examined the relationships between rel vant baseline 
variables and the change in EROS from pre- to post-treatment to identify potential 
covariates to include in the analysis (again considering the same set of theoretically-
derived potential covariates as used in the previous BADS and EROS analyses). No 
potential covariates were significantly related to change in EROS score from pre- to post-
treatment (all ps > .2). 
Next, we tested the interaction between treatment condition and time to examine 
whether there was a significant difference in the rate of change in EROS scores from pre- 
to post-treatment in the LET’S ACT vs. SC group. We used repeated measures ANOVAs 
with treatment group as the between subjects factor and scores on the EROS as the within 
subjects factor. Results indicated that a group x time interaction did not exist between the 
two groups on the EROS (F(1, 46) = 1.06, p = .31, η2 = .02), such that there was no 
difference between groups on increases in reward associated with activities from pre- to 
post-treatment (See Table 8 for results and Tables 18 and 19 for means by group).  
Chapter 4: Discussion 
4.1 Summary of Main Findings 
 The current study compared the LET’S ACT behavioral activation treatment for 
depression to a Supportive Counseling (SC) control condition among individuals in 
residential substance abuse treatment who presented with elevated depressiv  symptoms 
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(BDI-II score ≥ 12) or a current diagnosis of major depressive disorder (MDD) in their 
first week of residential substance abuse treatment. The study was a repliction and 
extension of the Daughters et al. (2008) study that established the initial efficacy of 
LET’S ACT in treating depression among substance users receiving residential treatment. 
The current study built on the previous findings by 1) including a contact-time matched 
control condition (SC) as opposed to TAU; 2) further examining the effect of LET’S 
ACT on substance abuse treatment dropout; 3) modifying the 6-session LET’S ACT 
protocol into an abbreviated 5-session version to extend its application to the high 
percentage of clients who have 30-day residential treatment contract lengths; and 4) 
building on the assessment of behavioral activation outcomes by including a measure of 
overall activation over the course of treatment using the Behavioral Activation for 
Depression Scale (BADS; Kanter et al., 2007). Specifically, the currently stud compared 
LET’S ACT to SC to examine differential effects on a) residential substance abuse 
treatment dropout; b) self-reported (BDI-II) and clinician-rated (HAMD) depressive 
symptoms; and c) measures of behavioral activation, including environmental 
reinforcement (EROS) and overall activation (BADS).  
Beginning with the effect on treatment dropout, we examined dropout in two 
ways: 1) predicting dropout (yes/no) during the initial 30-day period and 2) predicting 
days to dropout using a Cox proportional hazards survival regression analysis. Findings 
indicated treatment was significantly associated with dropout, such that a higher number 
of individuals in SC dropped out of treatment ( = 8; 27.6%) compared to in the LET’S 
ACT condition (n = 1; 12.5%); specifically, individuals in the SC condition were 





was also significantly associated with a shorter number of days to treatment dropout, such 
that SC predicted approximately an eightfold increase in the likelihood of dropout on any 
given day. This examination of the hazards ratio suggests that being placed in the LET’S 
ACT condition served as a protective factor from dropout. 
Regarding the effects on depression, GEE analyses indicated a significant 
treatment x time interaction predicting change in self-reported depressive symptoms 
(BDI-II scores) over the three assessment time points, such that individuals in the LET’S 
ACT condition demonstrated a significantly greater reduction in self-reported depressive 
symptoms compared to the SC condition. However, when this same interaction was 
tested using a repeated measures analysis of the first two time points (fr m baseline to 
post-treatment), a significant interaction was not evident. This suggests that group 
differences in the change in depressive symptoms are not evident immediately by post-
treatment (both the LET’S ACT groups and SC groups evidence decreases in BDI-II 
scores from pre- to post-treatment), but that only individuals in the LET’S ACT group 
continue to demonstrate significant reductions in depressive symptoms at the 2-week
follow up compared to SC.  
This finding is discussed further below in relation to the changes in behavioral 
activation observed. However, we first also must acknowledge that the lack of differences 
between groups in change in BDI-II score at the 1st post-treatment follow-up may be due 
to factors such as the effect of continued abstinence on reductions in depression as well 
as further adjustment to the treatment setting from the baseline to post-treatment 
assessments, both of which affect the sample at large. Further, it also should be noted that 





responsible for the differential effects, but the findings are consistent with Daughters et 
al. (2008). Daughters and colleagues found that the treatment x time interaction for BDI-
II scores was only evident at the 2-week follow up point and not by post-treatment, thus 
demonstrating that individuals in LET’S ACT continued to show greater reductions in 
depressive symptoms following treatment compared to those in the TAU condition 
(Daughters et al., 2008). Similar findings were also demonstrated in the current study for 
the assessment of clinician-rated depressive symptoms, such that a significant treatment x 
time interaction existed with clinician-rated depressive symptoms (HAMD) from baseline 
to the 2-week follow up, such that individuals in the LET’S ACT condition evidenced a 
significantly greater reduction in HAMD scores from baseline to the 2-w ek follow up 
compared to those in the SC condition.  
 Findings related to effects of treatment on behavioral activation process variables 
revealed a significant treatment x time interaction from pre- to post-treatment on the 
BADS, such that individuals in the LET’S ACT condition evidenced a significant 
increase in overall levels of behavioral activation compared to those in SC. However, th  
GEE analysis demonstrated that a significant interaction was not evident over the th ee 
time points, suggesting that the superior improvements in BA in the LET’S ACT 
condition vs. SC were not maintained at the 2-week follow up. Lastly, there were no 
significant differences between groups on changes in the EROS from baseline to post-
treatment or to the 2-week follow up, thus suggesting that perhaps measures of BA, and 
not necessarily environmental reinforcement, are more accurately tapping a otential 





In sum, the current study further demonstrates the efficacy of a 5-session version 
of LET’S ACT in reducing self-report and clinician-rated depressive sympto s at a 2-
week follow up assessment compared to SC. Findings also support the effect of LET’S 
ACT on an activation-related process variable, demonstrating a significantly greater 
improvement in levels of activation from pre-to post-treatment compared to SC. Lastly, 
and perhaps most importantly, the current study is the first to examine the effect of 
LET’S ACT on substance use outcomes (treatment dropout), such that LET’S ACT was 
associated significantly with lower rates of treatment dropout and greater delay to 
dropout compared to SC.  
It is interesting to note the timing of the significant changes in depression and 
behavioral activation. Changes in BA occurred during the 3-week treatment period and 
then appear to have slowed, while depressive symptoms in the two groups seem to have 
significantly differed in rates of change at the 2-week follow up period. This finding can 
be interpreted as a delayed effect of LET’S ACT on depressive symptoms, or that only in 
the LET’S ACT condition are effects on depressive symptoms lasting; however, longer-
term follow ups are needed to assess whether treatment effects remain beyond a 2-week 
period. We can also interpret this finding in relation to the changes in behavioral process 
variables in numerous ways. This finding may suggest a temporal relationship between 
changes in depression and behavioral activation, such that only following improvements 
in behavioral activation do we see reductions in depressive symptoms. Alternatively, this 
finding may suggest a “desynchrony” effect (Rachman & Hodgson, 1974), where 
behavior changes first and then depressive symptoms, but not necessarily indicating a 





variables that are not improving “in unison” (Rachman & Hodgson, 1974). Future work 
is needed to identify mechanisms of LET’S ACT that contribute to reduced depressive 
symptoms; testing these hypotheses will require more complex analyses of m diation, 
which were unable to be conducted in the current study given the small sample size 
(particularly at the 2-week follow up time point).   
Another related question is why a significant treatment x time interaction existed 
on the BADS from pre- to post-treatment but did not hold by the 2-week follow up. There 
are numerous possible interpretations of this finding. For example, perhaps the findings 
were not maintained by the 2-week follow up due to the fact that participants were in the 
same constricted environment for the 2 weeks following treatment. Due to the limited 
nature of activity options and one’s inability to determine independent schedules at th  
Center, perhaps there was little room for continued significant increases in levels of BA 
following treatment. Alternatively, this finding could be interpreted as demonstrating that 
therapist contact and guidance may be necessary to maintain increases in behavioral 
activation, and thus the increases in behavioral activation were no longer evident at th  2-
week follow up following termination of treatment. This would support the notion that 
future LET’S ACT protocols should incorporate either more focus on sustained changes 
following treatment or maintenance sessions to promote more lasting behavioral changes. 
Maintenance sessions were implemented in the Daughters et al. (2008) protocol; 
however, this was not feasible in the current study for individuals with only 30-day 
contract lengths. Perhaps future trials that include shorter term clients could implement 
maintenance LET’S ACT sessions in the initial period following treatment discharge to 





However, it is not clear if the lack of significant change in BA evidenced post-treatment 
necessitates a level of intervention that was provided in the treatment period; 
alternatively, this slowed improvement in BA following treatment could signal rathe  
impending problems in depressive symptoms if participants were followed out further. 
Lastly, we must also note that the small sample size at the 2-week follow up time oint 
may have precluded detection of meaningful differences between groups.  
Finally, we must also question the absence of an effect of treatment on measures 
of environmental reinforcement, or reward associated with activities. Interestingly, 
Daughters et al. (2008) did find a significant treatment x time interaction for EROS 
scores, such that individuals in LET’S ACT demonstrated significantly greater 
improvements in environmental reinforcement compared to the TAU group. In the 
current study, both groups demonstrated increases in levels of reinforcement from pre- to 
post-treatment; however, the rate of improvement across groups was similar. A possible 
explanation for why the findings did not replicate may be the difference in control 
groups, such that individuals in SC may be experiencing improvements in reinforcement 
and reward generated from activities as a result of the supportive, therapeutic process of 
SC. Given that this group did not evidence significant increases in overall activity level 
reflected by the BADS, the increases in reinforcement may not be due to added activities 
or behavioral repertoires, as targeted in LET’S ACT, but rather greater meaning or 
enjoyment derived from activities may be an active ingredient in SC that needs to be 
further examined in future research. 
This finding of a significant treatment x time interaction for BADS but not EROS 





specifically that LET’S ACT is associated with increases in activation and potentially 
increases in activities that may lead to positive reinforcement, but not necessarily 
increases in the actual levels of positive reinforcement experienced by activities. 
However, this finding needs to be further replicated, and we must also consider the 
context of the study, that this treatment took place at an inner-city residential substance 
abuse treatment center with very few activity options that may potentially d versify 
activities or be associated with increases in enjoyment. The limited activity options 
available for clients in a residential setting may potentially explain why LET’S ACT did 
not demonstrate an effect on reinforcement derived from activities and only on overall 
levels of activation. It would be interesting to examine longer-term changes i  BADS and 
EROS scores to see whether treatment has a longer term effect on enjoyment/reward 
associated with activities following treatment discharge, once an individual has more 
activity options and independence in selecting activities.  
4.2 Limitations/Future Directions 
A primary limitation of the current study concerns the modest sample size. The 
sample size issue in the current study was further complicated by treatment dropout being 
the main outcome, which contributed to a) low retention across study assessments, and b) 
differential sample sizes for the two conditions (with SC having lower sample sizes at the 
two post- and follow up assessments). With regard to the first issue, the low sampleize 
was of particular salience at the 2-week follow up assessment (n = 21), given that any 
individuals who dropped out of treatment or had a 30-day contract length did not receive 
a 2-week follow up assessment. This could have been rectified by tracking participants to 





and resources, we were not able to conduct these follow-up assessments. With regard to 
the second issue, that dropout differentially affected the SC sample size, we examined 
differences in baseline characteristics comparing individuals who dropped out of 
treatment vs. those who remained in treatment to detect whether those who dropped out 
were a more severely impaired group that could potentially affect resuls when not 
included in the depression and BA analyses. However, the comparison revealed no 
significant differences between groups that would reflect greater impair ent, including 
no differences at baseline on any of the main outcome variables or comorbid diagnoses 
(see Tables 13 and 14). Thus, although there was a smaller SC sample size at the post-
treatment and 2-week follow ups due to treatment dropout, we do not believe that any 
distinct characteristics of this subgroup would have significantly biased results. 
As a second related limitation resulting from treatment dropout being the main 
outcome, all individuals who dropped out of treatment in the 30-day study period did so 
prior to the post-treatment assessment, which precluded obtaining an assessment of 
change for these individuals. We thus could not examine change in our main outcome 
variables as predictors of dropout (e.g., depression, behavioral activation measures), and 
we also were not able to conduct any mediation analyses of treatment dropout. Given the 
brief nature of the 5-session treatment, we chose not to conduct a midpoint assessment 
that might have provided some data to that end, but we could do so in future studies if the 
treatment durations are a bit longer. The midpoint assessment (of at least the main 
outcome measures) would enable examination of the relationships between these 
variables among those who dropped out of treatment. Further, future studies may also 





the Center (i.e. track participants following dropout) so that treatment dropout does not 
preclude our ability to test study hypotheses.  
Although we were unable to examine potential mechanisms accounting for the 
effect of LET’S ACT on lower rates of treatment dropout, we were able to examine the 
baseline variables that were related to treatment retention. Interestingly, he only baseline 
clinical variables associated with treatment retention were related to behavioral 
activation, including baseline BADS total score ( = .27, p = .04), specifically the 
Activation subscale (r = .27, p = .04), and baseline EROS scores (r = .26, p = .05), 
indicating that individuals with higher levels of overall activation and reinforcement 
derived from activities at baseline were more likely to remain in treatment each given 
day. These correlations suggest a potential link between levels of behavioral 
activation/reinforcement and treatment retention. Although research has predominantly 
focused on the effect of depression on dropout (e.g., McKay et al., 2002; Tate et al., 
2004), perhaps future research is warranted in examining the effect of behavioral 
activation measures in relation to treatment dropout. Further, these measures of 
behavioral activation may be potential mechanisms to consider in future work when 
examining mediators of the effect of the LET’S ACT treatment on residential treatment 
dropout.   
A third limitation relates to the assessment of treatment dropout among 
individuals with differing contract lengths. We chose to only assess treatment dropout in 
the first 30 days of treatment rather than dropout overall as an attempt to equalize time in 
treatment among those with 30 vs. longer-term contract lengths. However, future work 





could argue that dropping out in the first 30 days is qualitatively different for someone in 
treatment 30 days vs. 60, 90, or 180 days. The current study included all contract lengths 
to maximize effectiveness with regard to adoptability by the Center for 30-day clients in 
particular; however, future studies that aim to replicate the effect of LET’S ACT on 
treatment dropout may consider only including certain contract lengths to minimize 
group differences (even if still limiting dropout to the first 30 days).   
Lastly, a final limitation concerned the nature of our sample. In the current study, 
we recruited low-income, largely minority substance users in residential substance abuse 
treatment, rather than a more demographically heterogeneous sample of substance users. 
Although low-income minority substance users in residential substance abuse treatment 
represent an underserved, at-risk population that may be most severe and most in need of 
prevention and intervention efforts, there is a possibility that the current findings may not 
generalize to a more demographically diverse sample, or a sample of individuals in a le s 
restrictive treatment setting. Additionally, the current study design, as well as treatment 
format, is not transportable to illiterate clients, which should be a consideration for future 
directions of this research. Although many of the primary outcome measures in this study 
were self-report, future assessments could incorporate audio-enhanced, computer assist d 
self-interviewing (audio-CASI technology) to include individuals with lower leve s of 
literacy. With regard to the applicability of the treatment components to individuals who 
are illiterate, homework assignments could be modified to use illustrative formats; for 
example, activity monitoring forms could utilize pictures rather than words, as suggested 
by Lejuez and colleagues in their revised BA manual (Lejuez, Hopko, Acierno, 





There exist numerous limitations and opportunities to expand upon and enhance 
this line of research to further establish the efficacy of LET’S ACT in improving 
depression and substance use outcomes. Beyond the clear need for a larger sample size 
and additional assessment time points, additional ideas for future studies that seek to 
expand upon the current work may include comparing LET’S ACT to another treatment 
(e.g., CBT) rather than a SC control condition to further establish the superior effects of 
LET’S ACT over CBT in this population, as well as to test the unique behavioral 
mechanisms of the LET’S ACT treatment. Future studies could examine a more complex 
mediation model to explain the effects of LET’S ACT on substance use outcomes, 
depression, and behavioral activation, as well as the inter-relationships of these variabl s 
as mechanisms of change.  
Finally, the current study was the first to begin to examine the ffectiveness of the 
LET’S ACT treatment in its ability to be administered across contract lengths in 
residential treatment by modifying the protocol to accommodate the large majority of 30-
day clients. Future work should continue to build on these findings to further establish he 
effectiveness of the treatment. For example, future investigations could explore the 
effectiveness of LET’S ACT when implemented in other types of treatment settings or 
with other types of substance using samples. Further, future studies could continue to est 
the ability to integrate LET’S ACT into a substance abuse treatment center(for xample 
by training counselors to implement the sessions and/or by incorporating the LET’S ACT 
group as part of the Center’s treatment schedule). In sum, there exists numerous 
opportunities to not only further establish efficacy of LET’S ACT in improving 














Table 1. Group differences: Demographic information  
 Overall 
(n = 58) 
 LA 
(n = 29) 
SC 
(n = 29) 
    Statistic 
    (LA vs. SC) 
  p 
Age, mean (SD) 44.78 (9.39) 44.21 (10.59) 45.34 (8.15) F (1, 56) = .21  .65 
Gender, % male 65.5 65.5 65.5 χ2 (1) = 0  1.0 
Marital Status    χ2 (3) = 1.5  .68 
     Single, %   81 82.8 79.3   
     Living with a partner as if married, %   5.2 3.4 6.9  
     Married but separated, %   12.1 10.3 13.8  
     Married, %   1.7 3.4 0  
Race    χ2 (3) = 1.41  .71 
     White, %   5.2 3.4 6.9   
     Black, %   89.7 93.1 86.2  
     Hispanic , %   3.4 3.4 3.4  
     Other, %   1.7 0 3.4  
Education    χ2 (1) = 3.39  .07 
     ≤ High school/GED, %   75.9 65.5 86.2   
     > High school/GED, %   24.1 34.5 13.8  
Total Annual Income     χ2 (1) = .49  .49 
     <$10,000, % 82.1 78.6 85.7   
     > $10,000, % 17.9 21.4 14.3   
Unemployed, %   84 82.8 82.8 χ2 (4) = 3.32  .51 















Table 2. Group differences: Baseline clinical variables+   
 Overall 
(n = 58) 
    LA 
(n = 29) 
    SC            
(n = 29) 
Statistic 
(LA vs. SC) 
p 
Contract Type        χ2 (4) = 8.13   .09 
     30-day, % 59 44.8 72.4        
     60-day, % 31 31 24.1   
     >60 days (90 or 180) 10 24.1 3.4   
Court Mandated, % yes 46.6 55.2 37.9     χ2 (1) = .28  .60 
CMR (Total), mean (SD) 74.81 (9.33) 74.62 (10.70) 75 (7.9)     F (1, 56)= .02  .88 
     Circumstances, mean (SD) 21.81 (4.59) 22.04 (5.19) 21.59 (3.98)     F (1, 56)= .14  .71 
     Motivation, mean (SD) 22.31 (3.42) 21.86 (4.06) 22.76 (2.64)     F (1, 56)= .99  .32 
     Readiness, mean (SD) 30.69 (3.98) 30.72 (3.65) 30.66 (4.35)     F (1, 56)= .01  .95 
Depression      
     Current MDD, %   60.3 58.6 62.1     χ2 (1) = .11 .74 
     Recurrent MDD, %   71 61.5 75.9     χ2 (1) = 2.25 .13 
On Psychotropic Medication, % 53.4 51.7 58.6     χ2  (1) = .43 .51 
Current Drug Dependences      
     Alcohol, %** 50.9 32.1 69      χ2  (1) = 7.73 .01 
     Marijuana, % 8.8 10.7 6.8      χ2  (1) = .26 .61 
     Cocaine, %   46.6 42.3 55.2      χ2  (1) =  .86 .35 
     Opioid, %   24.1 23.1 27.6      χ2 (1) = .29 .59 
     Multiple dependencies, % 47.4 35.7 58.6       χ2 (1) = 2.99 .08 
Current Anxiety Disorders      
     PTSD, %   21.8 25 18.5      χ2 (1)= .34 .56 
     GAD, %   17.5 17.9 17.2      χ2 (1)= .01 .95 
Axis II Comorbidity      
     BPD, %   36.8 50 27.6     χ2 (1) = 3.02 .08 
     ASPD, % 49.1 60.7 37.9     χ2 (1) = 2.96 .09 












Table 3. Group differences: Baseline levels of main outcome variables  
 Total Sample 
(n = 58) 
     LA 
   (n = 29) 
          SC 
   (n = 29) 
           Statistic 
         (LA vs. SC) 
p 
Depressive Symptoms     
     Clinician-Rated (HAMD), mean (SD)      5.51 (3.54) 5.96 (3.67)      5.07 (3.42) F (1, 55) = .91  .35 
     Self-Reported (BDI-II), mean (SD)          18.89 (9.41) 18.65 (10.91)      19.14 (7.77) F (1, 55) =.04  .85 
Behavioral Activation     
     BADS, mean (SD)                                    75.18 (24.12) 72.61 (25.19)      77.75 (23.15) F (1, 56) = .65  .42 
          Activation                                            18.76 (9.37) 18.33 (8.58)      19.18 (10.22) F (1, 56) = .12  .74 
          Avoidance/Rumination                        21.09 (11.37) 21.38 (10.66)      20.79 (12.21) F (1, 56) = .04  .85 
          Work/School Impairment                    19.63 (7.10) 18.76 (7.38)      20.50 (6.84) F (1, 56) = .87  .36 
          Social Impairment                               15.71 (7.63) 14.14 (7.56)      17.28 (7.51) F (1, 56) = 2.52  .12 
Environmental Reinforcement      
     EROS (mean, SD)                                    24.67 (4.81) 24.66 (4.98)      24.69 (4.71) F (1, 56) = .001   .98 














Table 4. Correlation matrix for measures of depression and behavioral activation 
 1   2   3   4   5    6   7   8 
1. BADS Total -- .40** .75** .77** .82** .58** -.39** -.28* 
2. BADS-AC  -- -.13 .04 .20 .62** -.14 -.09 
3. BADS-AR   -- .57** .52** .28* -.29* -.21 
4. BADS-WS    -- .62** .25 -.27* -.18 
5. BADS-SI     -- .42** -.37* -.29* 
6. EROS Total      -- -.30* -.36** 
7. HAMD total       -- .40** 
8. BDI-II        -- 































Table 5. Intent-to-treat logistic regression predicting residential tre tment dropout  
Variable B SE Wald OR (95% CI) P 
Step 1      


























Variable B SE Wald HR (95% CI) p 
Step 1      







Table 7. GEE analysis predicting BDI-II change from baseline to 2-week follow up 
 










Main effects     
  Time (centered) -5.58 1.21 21.38 .00 
  Gender -1.99 2.53 0.62 .43 
  Treatment -2.2 2.27 .94 .33 


























Variable   Statistic η2 p 
Depressive Symptoms     
     Self-Reported (BDI-II)      F(1, 44) = .01       0 .99 
     Clinician-Rated (HAMD)*   F(1, 18) = 4.78      .21 .04 
Behavioral Activation     
     BADS*      F(1, 45) = 5.39      .10 .03 
          Activation                                              F(1, 46) =   .03      .01 .87 
          Avoidance/Rumination                    F(1, 46) = 2.01      .04 .15 
          Work/School Impairment                       F(1, 46) = 2.41      .05 .13 
          Social Impairment*                                  F(1, 46) = 6.20      .12 .02 
Environmental Reinforcement      
     EROS        F(1, 46) = 1.06      .02 .31 
















Table 9. GEE analysis predicting BADS change from baseline to 2-week follow up 
 










Main effects     
  Time (centered) 10.52 4.83 4.75 .03 
  Treatment -6.44 6.87 .88 .35 











Table 10. GEE analysis predicting EROS change from baseline to 2-week follow up 
 










Main effects     
  Time (centered) 1.24 1.03 1.45 .23 
  Treatment -.41 1.43 .08 .78 














(n = 29) 
SC 
(n = 29) 
           Statistic 
       (LA vs. SC) 
  p 
Treatment Satisfaction, mean (SD)  25.46 (4.17) 26.3 (7.04)     F (1, 46) = .266 .61 
Working Alliance (WAI), mean (SD) 27.37 (11.38) 25.8 (8.28)     F (1, 46) = .273  .60 
Note. * p < .05, ** p < .01, *** p < .001 








Secondary Tables  
 
 
Table 12. Demographic variables related to residential treatment dropout (yes/no) 
 Dropout Yes 
(n = 8) 
Dropout No 
(n = 50) 
    Statistic 
     
  p 
Age, mean (SD) 41.88 (5.79) 45.24 (9.8) F (1, 56) = .89 .35 
Gender, % male 87.5 62 χ2 (1) = 1.99 .16 
Marital Status   χ2 (3) = 2.8 .42 
     Single, %   62.5 84   
Race   χ2 (3) = 1.45 .69 
     Black, %   87.5 90  
Education   χ2 (1) = .86 .35 
     Less than high school/GED, %   87.5 72   
     More than high school, %   12.5 28  
Total Annual Income    χ2 (1) = .18 .67 
     <$10,000, % 87.5 81.3   
     > $10,000, % 12.5 18.8   
Employment   χ2 (4) = 7.96 .09 
    Unemployed, %   75 85.7   








Table 13. Baseline clinical variables related to residential treatment dropout (yes/no) 
 Dropout Yes 
(n = 8) 
Dropout No            




Treatment*       χ2 (1) = 5.22     .02 
     LET’S ACT 12.5 56   
     SC 87.5 44   
Contract Type       χ2 (1) = .06   .81 
     30-day, % 62.5 58        
     >30 days (60, 90 or 180), % 37.5 42   
Court Mandated, % yes 37.5 48     χ2 (1) = .31  .58 
CMR (Total), mean (SD) 79.25 (8.96) 74.10 (9.27)     F (1, 56)= 2.14  .15 
     Circumstances, mean (SD) 23.13 (5.17) 21.6 (4.51)     F (1, 56)= .76  .39 
     Motivation, mean (SD) 23.75 (2.55) 22.08 (3.5)     F (1, 56)= 1.66  .20 
     Readiness, mean (SD) 32.38 (3.46) 30.42 (4.03)     F (1, 56)= 1.68  .20 
Depression     
     Current MDD, %   87.5 56     χ2 (1) = 2.86 .09 
     Recurrent MDD, %   75 65.3     χ2 (1) = .29 .59 
On Psychotropic Medication, %** 100 46     χ2  (1) = 8.08 .004 
Current Drug Dependences     
     Alcohol, % 75 46.9      χ2  (1) = 2.17 .14 
     Marijuana, % 12.5 8.2      χ2  (1) = .16 .69 
     Cocaine, %   62.5 46.9      χ2  (1) =  .67 .41 
     Opioid, %   25 24.5      χ2 (1) = .01 .98 
     Multiple dependencies, % 75 42.9       χ2 (1) = 2.85 .09 
Current Anxiety Disorders     
     PTSD, %   25 21.3      χ2 (1)= .06 .81 
     GAD, %   12.5 18.4      χ2 (1)= .16 .69 
Axis II Comorbidity     
     BPD, %   25 18.4      χ2 (1) = .73 .39 
     ASPD, % 37.5 51      χ2 (1) = .50 .48 








Table 14. Baseline levels of outcome variables related to residential treatment dropout (yes/no) 
  Dropout Yes 
   (n = 8) 
  Dropout No 
    (n = 50) 
    Statistic 
 
    p 
Depressive Symptoms     
     Clinician-Rated (HAMD), mean (SD)       4.50 (3.5)      5.67 (3.56) F (1, 55) = .75  .39 
     Self-Reported (BDI-II), mean (SD)           18.25(10.01)      19.00 (9.42) F (1, 55) = .04  .84 
Behavioral Activation     
     BADS, mean (SD)                                     64.58 (29.92)      76.87 (22.97) F (1, 56) = 1.82 .18 
          Activation                                             13.33 (8.23)      19.62 (9.32) F (1, 56) = 3.23 .08 
          Avoidance/Rumination                         18.50 (16.35)      21.50 (10.53) F (1, 56) = .48 .49 
          Work/School Impairment                     17.50 (5.15)      19.97 (7.35) F (1, 56) = .83 .37 
          Social Impairment                                15.25 (7.61)      15.78 (7.71) F (1, 56) = .03 .86 
Environmental Reinforcement      
     EROS (mean, SD)                                     22.00 (3.82)      25.10 (4.84) F (1, 56) = 2.97 .09 














Table 15. Group differences by contract length (30-day vs. 60, 90, and 180): Demographic informat on  
  30-day 
(n = 34) 
60, 90, 180-day 
(n = 23) 
    Statistic 
    (30 vs. 60, 90, 180) 
  p 
Age, mean (SD) 44.29 (8.64) 45.46 (10.51) F (1, 56) = .21 .65 
Gender, % male 67.6 62.5 χ2 (1) = .17 .69 
Marital Status   χ2 (3) = 1.50 .68 
     Single, %   82.4 79.2   
Race   χ2 (3) = 3.61 .31 
     Black, %   88.2 91.7  
Education   χ2 (1) = .57 .45 
     Less than high school/GED, %   79.4 70.8   
     More than high school/GED, %   20.6 29.1  
Total Annual Income    χ2 (1) = .46 .79 
     <$10,000, % 82.4 75   
     > $10,000, % 17.6 25   
Unemployed, %   88.2 83.3 χ2 (4) = 3.07 .54 


























Table 16. Group differences by contract length (30-day vs. 60, 90, and 180): Baseline clinical variables+   
  30-day 
(n = 34) 
 60, 90, 180-day           
(n = 23) 
 Statistic 
(30 vs. 60, 90, 180) 
p 
CMR (Total), mean (SD) 73.82 (8.57) 76.21 (10.34)     F (1, 56)= .92  .34 
     Circumstances, mean (SD) 21.09 (4.37) 22.84 (4.79)     F (1, 56)= 2.08  .16 
     Motivation, mean (SD) 22.18 (3.79) 22.50 (2.89)     F (1, 56)= .12  .73 
     Readiness, mean (SD) 30.56 (3.64) 30.88 (4.50)     F (1, 56)= .09  .77 
Depression     
     Current MDD, %   61.8 58.3     χ2 (1) = .07 .79 
     Recurrent MDD, %   66.7 66.7     χ2 (1) = 0 1.00 
On Psychotropic Medication, % 50.0 58.3     χ2  (1) = .39 .53 
Current Drug Dependences     
     Alcohol, %* 63.6 33.3      χ2  (1) = 5.11 .02 
     Marijuana, % 9.1 8.3      χ2  (1) = .01 .92 
     Cocaine, %   39.4 62.5      χ2  (1) =  2.97 .10 
     Opioid, %   18.2 33.3      χ2 (1) = 1.72 .19 
     Multiple dependencies, % 48.5 45.8       χ2 (1) = .04 .84 
Current Anxiety Disorders     
     PTSD, %   19.4 25      χ2 (1)= .25 .62 
     GAD, %   21.2 12.5      χ2 (1)= .73 .39 
Axis II Comorbidity     
     BPD, %*   37.5 54.2     χ2 (1) = 4.24 .04 
     ASPD, % 42.4 58.33     χ2 (1) = 1.41 .24 









Table 17. Group differences by contract length (30-day vs. 60, 90, and 180): Baseline leves of the main outcome variables  
    30-day     
 (n = 34) 
        60, 90, 180 
   (n = 23) 
           Statistic 
    (30 vs. 60, 90, 180) 
p 
Depressive Symptoms     
     Clinician-Rated (HAMD), mean (SD)      5.18 (3.62)      6.00 (3.44) F (1, 55) = .74  .39 
     Self-Reported (BDI-II), mean (SD)           19.73 (8.11)      17.75 (11.04) F (1, 55) = .61  .44 
Behavioral Activation     
     BADS, mean (SD)                                     74.20 (24.19)      76.57 (24.48) F (1, 56) = .134  .72 
          Activation                                             19.12 (9.38)      18.24 (9.52) F (1, 56) = .12  .73 
          Avoidance/Rumination                         19.79 (11.93)      22.92 (10.49) F (1, 56) = 1.06  .31 
          Work/School Impairment                     20.25 (6.21)      18.75 (8.27) F (1, 56) = .62  .43 
          Social Impairment                               15.03 (7.97)      16.67 (7.18) F (1, 56) = .64  .43 
Environmental Reinforcement      
     EROS (mean, SD)                                     24.29 (4.50)      25.21 (5.27) F (1, 56) = .51  .48 












Table 18. Mean values of main outcome variables at baseline and post: Let’s Act only 
 
Variable 
        Baseline 
        (n = 29) 
Post  
(n = 28) 
Depressive Symptoms     
     Self-Reported (BDI-II), mean (SD) 18.65 (10.91) 13.46 (9.71)  
Behavioral Activation   
     BADS, mean (SD)***                               72.61 (25.19) 86.01 (21.5)   
          Activation                                         18.33 (8.58) 20.95 (10.05)  
          Avoidance/Rumination*                   21.38 (10.66) 25.89 (9.90) 
          Work/School Impairment                  18.76 (7.38) 20.97 (6.84)     
          Social Impairment**                             14.14 (7.56) 18.19 (6.71) 
Environmental Reinforcement    
     EROS (mean, SD)                                  24.66 (4.98) 26.12 (4.86)     
 Baseline  
(n = 29) 
 2-week FU                                  
(n = 15) 
Depressive Symptoms   
     Clinician-Rated (HAMD), mean (SD)**    5.96 (3.67)  3.60 (3.85) 











Table 19. Mean values of main outcome variables at baseline and post: SC only 
 
Variable 
        Baseline 
        (n = 29) 
Post  
(n = 20) 
Depressive Symptoms   
     Self-Reported (BDI-II), mean (SD)      19.14 (7.77) 12.90 (7.73) 
Behavioral Activation   
     BADS, mean (SD)                                   77.75 (23.15) 85.33 (26.4)   
          Activation                                              19.18 (10.22) 23.68 (11.11)      
          Avoidance/Rumination                        20.79 (12.21) 23.00 (10.46) 
          Work/School Impairment                       20.50 (6.84) 20.65 (7.53)    
          Social Impairment                                  17.28 (7.51) 18.00 (7.88)      
Environmental Reinforcement    
     EROS (mean, SD)                                       24.69 (4.71)  25.75 (4.95)     
       Baseline 
      (n = 29) 
2-week FU  
(n = 6) 
Depressive Symptoms   
     Clinician-Rated (HAMD), mean (SD)          5.07 (3.42) 3.33 (2.34)   












n = 63 
 
   Refused n = 1 
   Not eligible n = 4 
 
SC 
n = 29 
LET’S ACT 
n = 29 
Randomized 
n = 58 
 
Baseline n = 29 
n = 1 dropout after baseline 
(noncompliant) 
Post Assessment  = 28 
n = 0, dropouts 
2-week follow up n = 15 
n = 10, 30-day contract 
n = 2, medical discharge 
n = 1, early discharge to 
transitional housing 
5 Tx Sessions  
Baseline n = 29 
n = 1 dropout after 
baseline (voluntary) 
 
5 Tx Sessions  
Post Assessment  = 20 
n = 6 dropouts (voluntary) 
n = 2, legal discharge 
2-week follow up n = 6 
n = 13, 30-day contract 
n = 1, legal discharge 
 























Predicting MDD at the 2-week follow up assessment  
 
As a supplementary analysis to examine whether treatment group was associated 
with the likelihood of having an MDD diagnosis at the 2-week follow up, we conducted a 
logistic regression predicting MDD diagnosis at the follow up (yes/no). Before 
conducting the analysis, we also examined any baseline and demographic variables th t 
may be related to MDD at the 2-week follow up. No baseline variables were significantly 
related to MDD at the 2 week follow up (all ps > .10), including baseline MDD status (χ2 
(1) = 3.7, p = .10). Therefore, in the first step of the logistic regression analysis, we 
entered treatment condition (LET’S ACT = 1, SC = 0). Results did not indicate a main 
effect for treatment condition, such that there was no significant difference in lik lihood 
of having an MDD diagnosis at the 2-week follow up based on treatment condition (OR = 
2.00, CI = .24-16.61, p = .52).   
Predicting MDD remission at the 2-week follow up in the current study has 
significant limitations, mainly due to small sample size and difficulty of interpretation. 
We were unable to include only individuals who met criteria for MDD at the screening 
given that this would significantly limit sample size. Of individuals who had a 2-week 
follow up assessment and met criteria for MDD at baseline (n = 9), 4 met criteria for 
MDD at the 2-week follow up, and 5 demonstrated remission. However, 8 of these 
individuals were in LET’S ACT and only 1 in SC, and thus we could not control for 
baseline MDD to examine whether treatment predicted MDD remission at the 2-we k 
follow up given that there was only 1 SC participant that could be included. Thus, these 






not predicting MDD remission but rather MDD status at the 2-week follow up regardless 
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